aspirin and rivaroxaban

aspirin has been researched along with rivaroxaban in 373 studies

Research

Studies (373)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (0.80)	29.6817
2010's	204 (54.69)	24.3611
2020's	166 (44.50)	2.80

Authors

Authors	Studies
Carvalho, F; Correia-da-Silva, M; Cunha-Ribeiro, LM; Duarte, B; Marques, F; Pinto, MM; Sousa, E	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Boccarelli, A; Cabral, LM; de Pádula, M; Di Mauro, GD; Ferorelli, S; Fortuna, CG; Iaselli, M; Miciaccia, M; Pati, ML; Perrone, MG; Rodrigues Pereira da Silva, LC; Sathler, PC; Scilimati, A; Souza Domingos, TF; Vacca, A; Vitale, P	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Becka, M; Kubitza, D; Mueck, W; Zuehlsdorf, M	1
Go, G; Gonzalez Della Valle, A; Lyman, S; Salvati, EA; Sharrock, NE	1
Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A	1
Cohen, AT; Nandini, B; Ota, S; Wills, JO	1
Shakib, S; Tadros, R	1
Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N	1
Dibattiste, PM; Ringwala, SM; Schneider, DJ	1
Halperin, JL; Varughese, CJ	1
Bhatt, DL; Kar, S	1
Callahan, S; Goldsberry, A; Kim, G; Yoo, S	1
Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E	1
Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW	1
Becka, M; Gouya, G; Kapiotis, S; Kubitza, D; Mueck, W; Wolzt, M	1
Finsterer, J; Stöllberger, C	1
Diener, HC	1
Bates, P; Culpan, P; El-Daly, I; Reidy, J	1
Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M	1
Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y	1
Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS	1
He, B; Kun, L; Liu, X; Wu, B	1
Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD	1
Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD	1
Gupta, K; Singh, D; Vacek, JL	1
Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA	1
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA	1
Sun, K; Tian, S; Wang, Y; Zou, Y	1
Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S	1
Gislason, G; Sørensen, R	1
Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T	1
Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA	1
Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X	1
Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M	1
Aguiar, C; Chatzitheofilou, I; Fonseca Santos, I; McLeod, E; Morais, J; Pereira, S	1
Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B	1
Bultas, J	1
Calıskan, A; Demirtas, S; Guclu, O; Kaplan, I; Karahan, O; Tezcan, O; Yavuz, C; Yazıcı, S	1
Heitmeier, S; Laux, V; Perzborn, E	1
Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Haskell, L; Holberg, G; Kakkar, A; Lensing, AW; Prandoni, P; Prins, M; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS	1
Gao, F; Liu, XL; Shen, H; Wang, ZJ; Yang, SW; Zhou, YJ	1
Dogné, JM; Sennesael, AL; Spinewine, A	1
Ang, ES; De Silva, DA; Fabiaña, N; Ramaswami, AP	1
Bai, Y; Han, J; Jiang, W; Liu, X; Yang, F; Zhang, G; Zhao, G	1
Al-Dam, A; Eichhorn, W; Gröbe, A; Hanken, H; Heiland, M; Kluwe, L; Koehnke, R; Smeets, R; Wikner, J	1
Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL	1
Forslund, T; Hjemdahl, P; Wettermark, B	1
Hussein, A; Saliba, W; Wazni, OM	1
Lu, JH; Lu, N; Miao, SG; Yang, Y; Zhang, XG	1
Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R	1
Baker, D; Narasimhan, S; Wilsmore, B	1
Bianco, D; Morassi, A; Nakamura, RK; Park, E; White, GA	1
Briere, JB; Evers, T; Hori, M; Ikeda, S; Koretsune, Y; Matsuda, S; Montouchet, C; Okumura, K; Rossi, B; Ruff, L; Watanabe-Fujinuma, E	1
Adamo, A; Bilora, F; Pomerri, F; Prandoni, P	1
Jiang, SB; Li, L; Liu, XZ; Ma, J; Zhang, BJ; Zhang, BK	1
Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW	1
Bordignon, S; Chun, JK; Dugo, D; Fürnkranz, A; Konstantinou, A; Perrotta, L; Schmidt, B	1
Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F	1
Musgrave, KM; Powell, J	1
Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE	1
Baber, U; Dangas, GD; Giustino, G; Guimarães, AH; Hemmrich, M; Mehran, R; Thomitzek, K; Tijssen, J; Valgimigli, M; van Es, GA; Volkl, AA; Vranckx, P; Welsh, RC; Wildgoose, P; Windecker, S; Zazula, A	1
Bauersachs, R; Berkowitz, SD; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Freitas, MCS; Haskell, L; Holberg, G; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS	1
Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J	1
Gurbel, PA; Tantry, US	1
Burden, AM; de Boer, A; de Vries, F; Ebbelaar, C; Schalekamp, T; Souverein, P; Stolk, LM; Ten Cate-Hoek, A	1
Huynh, K	2
Barmparas, G; Bosarge, P; Brown, CV; Bukur, M; Carrick, MM; Catalano, RD; Coimbra, R; Holly-Nicolas, J; Inaba, K; Kaminski, S; Klein, AL; Kobayashi, L; Kopelman, T; Ley, EJ; Martinez, EM; Moore, FO; Murry, J; Nirula, R; Paul, D; Quick, J; Rivera, O; Schreiber, M	1
Churilov, L; Hardidge, AJ; Suen, K; Westh, RN	1
Bang, SM; Lee, J; Lee, JO; Lee, JY; Yhim, HY	1
Dunn, A	1
Steurer, J	2
Jolobe, OMP	1
Huisman, MV; Klok, FA	1
Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Chen, E; Commerford, PJ; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Dans, AL; Diaz, R; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Misselwitz, F; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J	1
Agnelli, G; Becattini, C; Benedetti, R; Fontana, M; Giustozzi, M; Imberti, D	1
Lim, GB	3
Kaymaz, C	1
Yılmaz, MB	1
Hitti, E; Ismail, R; Zaghrini, E	1
Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S	1
Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J	1
Kohlman-Trigoboff, D	1
Borzak, S	1
Brodie, MM; Newman, JC; Rockey, DC; Smith, T	1
Patrono, C	1
Aboyans, V; Abtan, J; Anand, S; Bhatt, DL; Bosch, J; Branch, KR; Connolly, SJ; Darmon, A; Ducrocq, G; Dyal, L; Eagle, KA; Eikelboom, JW; Elbez, Y; Fox, KAA; Keltai, K; Probstfield, J; Sorbets, E; Steg, PG; Yusuf, S	1
Ramli, A; Robertson, L; Yeoh, SE	1
Eikelboom, JW; Kruger, PC; Yusuf, S	1
Angelopoulos, G; Attal, R; Lazareth, I; Priollet, P	1
Birnie, DH; Champagne, J; Essebag, V; Gupta, D; Ha, ACT; Healey, JS; Heidbuchel, H; Hill, MD; Hindricks, G; Kirchhof, P; Sanders, P; Sharma, M; Verma, A; Wells, G; Wyse, DG	1
Calabrò, P; Gragnano, F; Visconti, LO	1
Abianui, A; Anderson, DR; Andreou, P; Belzile, E; Bohm, E; Carrier, M; Coyle, D; Crowther, M; Dolan, S; Doucette, S; Dunbar, M; Fisher, W; Forsythe, M; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, MJ; MacDonald, SJ; Murnaghan, J; Pelet, S; Pleasance, S; Rodger, MA; Theriault, C; Vendittoli, PA; Wells, PS; Zukor, D	1
Chun, K; Lakha, S; Png, CYM; Ting, W	1
Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S	1
Amarenco, P; Ameriso, SF; Arauz, A; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Dávalos, A; DeVries Basson, MM; Eckstein, J; Endres, M; Gagliardi, R; Hankey, GJ; Hart, RG; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, K; Mundl, H; Ntaios, G; O'Donnell, M; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, DS; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, J; Yoon, BW	1
Abola, MT; Aboyans, V; Anand, SS; Bhatt, DL; Bosch, J; Branch, KRH; Caron, F; Connolly, SJ; Cook-Bruns, N; Dyal, L; Eikelboom, JW; Fox, KAA; Keltai, K; Lanius, V; Verhamme, P; Yusuf, S	1
Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Homering, M; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; Tamm, M; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS	1
Mant, J	1
Brewster, A; Burchette, JE; El-Bazouni, H; Lindquist, DE; Odle, BL; Stewart, DW; Waldroup, C	1
Arioli, D; Donelli, D; Leone, MC; Morini, L; Negri, EA	1
Nie, L; Xu, W; Yang, Z; Zhang, T	1
Anand, SS; Bauersachs, R; Berkowitz, SD; Bonaca, MP; Capell, WH; Chen, E; Debus, ES; Fanelli, F; Haskell, L; Hiatt, WR; Kittelson, JM; Nehler, MR; Patel, MR	1
Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW	1
Gibler, WB	1
Anand, SS; Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Harrington, RA; Steg, PG; Yusuf, S	1
Leys, D; Moulin, S	1
Karakas-Torgut, A; Mo, Y; Pham, AQ	1
Azboy, I; Groff, H; Parvizi, J	1
Krug, K; Laux, G; Peters-Klimm, F; Schwill, S; Szecsenyi, J; van Lieshout, J; Wensing, M	1
Chan, NC; Weitz, JI	4
Espinola-Klein, C	2
Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Cohen, AT; Davidson, BL; Gebel, M; Homering, M; Lensing, AWA; Levitan, B; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS; Yuan, Z	1
Schrage, B; Westermann, D; Zeymer, U	1
Chiang, CE; Huang, WY; Lee, M; Ovbiagele, B; Singer, DE; Weng, HH; Wu, YL	1
Agewall, S; Niessner, A	1
Carlsen, SM; Giannadakis, C; Gulati, AM; Gulati, S; Jakola, AS; Jensberg, H; Madsbu, MA; Salvesen, Ø; Solheim, O; Øie, LR	1
Bawa, H; Dirschl, DR; Luu, HH; Weick, JW	1
Ashton, V; Beyer-Westendorf, J; Crivera, C; Haskell, L; Laliberté, F; Lefebvre, P; Lejeune, D; Lensing, AWA; Levitan, B; Prandoni, P; Prins, MH; Schein, J; Wells, PS; Xiao, Y; Yuan, Z; Zhao, Q	1
Anand, SS; de Vries, TAC; Eikelboom, JW; Kruger, PC	1
Boudoulas, KD; Taylor, M	1
Ademi, Z; Liew, D; Tonkin, A; Zomer, E	1
Frieden, RW	1
Ameriso, SF; Bangdiwala, S; Berkowitz, SD; Connolly, SJ; Endres, M; Hart, RG; Kasner, SE; Lavados, P; Lindgren, A; Lutsep, H; Messé, SR; Muir, K; Mundl, H; Nedeltechev, K; Olavarria, V; Perera, K; Santo, G; Sharma, M; Shoamanesh, A; Spence, JD; Swaminathan, B; Veltkamp, R	1
Al-Akchar, M; Bhattarai, M; Chami, Y; Hudali, T; Robinson, R; Vogler, C	1
Hoppe, UC; Jung, C; Lauten, A; Lichtenauer, M; Navarese, EP; Wernly, B	1
Meier, B	1
Bhatt, DL; Boden, WE	1
Anand, SS; Bhagirath, VC; Eikelboom, JW	1
Ademi, Z; Hird, TR; Liew, D; Owen, AJ; Reid, CM; Si, S; Tonkin, A; Zomer, E	1
Danchin, N; Eikelboom, J; Ferrières, J; Fox, KAA; Puymirat, E; Schiele, F; Simon, T	1
Filis, K; Kakkos, SK; Karaolanis, G; Moris, D; Sigala, F; Tsilimigras, DI	1
Chuaychoosakoon, C; Hongnaparak, T; Iamthanaporn, K; Iemsaengchairat, C; Tuntarattanapong, P; Yuenyongviwat, V	1
Bhatt, DL; Bosch, J; Branch, KRH; Connolly, S; Copland, I; Dagenais, F; Dagenais, G; Eikelboom, J; Fox, KAA; Kong, Y; Lamy, A; Lee, SF; Lonn, E; Marsden, T; Sheth, T; Straka, Z; Widimsky, P; Yusuf, S; Zheng, Z; Zhu, J	1
Alexander, JH	1
Aboyans, V; Alings, M; Berkowitz, SD; Bhatt, DL; Bosch, J; Bruns, NC; Catanese, L; Connolly, SJ; Eikelboom, JW; Fox, K; Ha, JW; Hart, RG; Keltai, K; Maggioni, A; Ng, KKH; O'Donnell, M; Sharma, M; Shestakovska, O; Tonkin, A; Varigos, J; Yusuf, S	1
Nelson, AJ; Nicholls, SJ	1
Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA	1
Fazio, S; Weitz, JI	1
Coppens, M; Eikelboom, JWA; Weitz, JI	1
Aboyans, V; Anand, SS; Bauersachs, R; Bosch, J; Debus, ES; Eikelboom, JW; Mazzolai, L; Nehler, M; Nikol, S; Pastori, D; Patel, MR; Ricco, JB; Tanguay, JF; Verhamme, P; Violi, F	1
Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R	1
Melis, M; Ricci, S; Toni, D	1
Elkind, M; Fekete, Z; Jiang, Z; Lucky, M	1
Barylski, M; Filipiak, KJ; Gierlotka, M; Legutko, J; Lesiak, M; Stępińska, J; Witkowski, A; Wojakowski, W	1
Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W	1
Choi, KS; Kang, J; Kim, HA; Lee, JY; Park, SH; Rhie, SJ	1
Eikelboom, JW; Kristensen, SD; Maeng, M; Olesen, KKW; Thim, T; Würtz, M	1
Bauersachs, R; Cohen, AT	1
Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X	1
Gamal, A; George, S; Onwordi, ENC; Zaman, A	1
Alavinia, SM; Kumbhare, D; Liang, J	1
Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F	1
Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Commerford, PJ; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Dans, A; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, T; Hart, RG; Hori, M; Kakkar, A; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, K; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J	1
Connolly, SJ; Eikelboom, JW; Fox, KAA; Metsarinne, KP; Shestakovska, O; Yusuf, S	1
Patel, MR	1
Kontogiannis, C; Moris, D; Sigala, F; Tsilimigras, DI	1
Eikelboom, J; Lamy, A	1
Bhupathi, V; Shanker, A	1
Bonnet, D; Dong, X; Harris, KC; Jefferies, J; Justino, H; Li, JS; McCrindle, BW; Michelson, AD; Pina, LM; Samtani, MN; Zhang, L	1
Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J	1
Eikelboom, JW; Guzik, TJ; Kruger, PC	1
Cairns, JA; DeMets, D; Eikelboom, JW; Shestakovska, O; Yusuf, S	1
Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J	1
Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC	1
Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S	1
Imberti, D; Mastroiacovo, D; Pomero, F	1
Davidson, BL; Tomkowski, WZ	1
Butler, S; Harris, IA; Kerr, DL; Read, AC	1
Thomas, R	1
Anand, SS; Avezum, AA; Bhatt, DL; Bosch, J; Connolly, SJ; Cook Bruns, N; Dyal, L; Eikelboom, JW; Fox, KAA; Neumann, C; Probstfield, J; Widimsky, P; Yusuf, S	1
Abtan, J; Bhatt, DL; Darmon, A; Ducrocq, G; Elbez, Y; Montalescot, G; Ohman, EM; Popovic, B; Röther, J; Sorbets, E; Steg, PG; Wilson, PF; Zeymer, U	1
Bonaca, MP; Hess, CN; Hiatt, WR	1
Almendro-Delia, M; Bellmunt, S; Cosín-Sales, J; García-Moll, X; Hernández, JL; Lozano, F; Mazón, P; Riera-Mestre, A; Sanmartín, M; Suarez Fernández, C	1
Deng, H; Jiang, M; Li, L; Lin, Y; Xie, J; Xie, X	1
Corley, DA	1
Amarenco, P; Berkowitz, SD; Bornstein, N; Camps-Renom, P; Connolly, SJ; Cucchiara, B; Gagliardi, RJ; Hart, RG; Korompoki, E; Lang, W; Lavados, P; Makaritsis, K; Marti-Fabregas, J; Meseguer, E; Milionis, H; Mundl, H; Ntaios, G; Papavasileiou, V; Siegler, JE; Swaminathan, B; Vemmos, K	1
Taylor, BL; Tirschwell, DL	1
Cleland, JGF; Pellicori, P	1
Barry, P; Cobb, J; Dawoud, D; Dias, S; Glen, J; Griffin, X; Lewis, S; Reed, M; Sharpin, C; Stansby, G	1
Albendín Iglesias, H; Arregui Montoya, F; Bailén Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Lova Navarro, A; Manzano-Fernández, S; Pascual Figal, DA	1
Anand, SS; Bhagirath, VC; Kaplovitch, E; McClure, GR; Narula, S	1
Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S	2
Abbate, O; Black, CK; Camden, RC; Evans, KK; Fan, KL; Lu, K	1
Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J	1
Kozieł, M; Lip, GYH	1
Batko, BD; Courtney, PM; Edmiston, TA; Hannon, CP; Levine, BR; Manista, GC; Sexton, AC	1
Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Cook-Bruns, N; Eikelboom, JW; Felix, C; Fox, KAA; Hart, RG; Maggioni, AP; Moayyedi, P; O'Donnell, M; Rydén, L; Shestakovska, O; Verhamme, P; Widimsky, P; Yusuf, S; Zhu, J	1
Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S	1
Amarenco, P; Berkowitz, SD; Bornstein, NM; Connolly, SJ; Endres, M; Hart, RG; Lang, W; Liu, YY; Meseguer, E; Molina, CA; Mundl, H; Ntaios, G; Ozturk, S; Pagola, J; Pearce, LA; Sen, S	1
Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S	1
Bode, C; Duerschmied, D; Olivier, CB	1
Chesnikova, AI; Frolov, DV; Gridasova, RA; Kanorskii, SG; Kastanayan, AA; Khaisheva, LA; Khripun, AV; Pagaev, FP; Sadovoy, VI; Sidorov, RV; Terent'ev, VP; Tuaeva, IB; Vasuk, YA	1
Behne, A; Hardung, D; Langhoff, R	1
Borzak, S; Dayanand, P	1
Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KA; Maggioni, AP; Shestakovska, O; Vanassche, T; Verhamme, P; Widimsky, P; Yusuf, S	1
Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK	1
Eikelboom, JW; Moayyedi, P; Yusuf, S	1
Bronswijk, M	1
Donzelli, A; Giudicatti, G	1
Ramacciotti, E; Weitz, JI	1
Popkirov, S	1
Gladstone, DJ; Hart, RG; Healey, JS	1
Baldus, S; Dangas, GD; De Backer, O; Gilard, M; Giustino, G; Guimarães, AHC; Gullestad, L; Herrmann, HC; Kini, A; Mack, M; Makkar, RR; Mehran, R; Möllmann, H; Moreno, R; Schäfer, U; Seeger, J; Søndergaard, L; Tchétché, D; Thomitzek, K; Tijssen, JGP; Valgimigli, M; van Amsterdam, RGM; Volkl, AA; von Lewinski, D; Vranckx, P; Welsh, RC; Wildgoose, P; Windecker, S; Wöhrle, J; Zazula, A	1
Abdel-Wahab, M; Arnold, M; Balan, P; Blanke, P; Dangas, GD; De Backer, O; Guimarães, AHC; Jeger, RV; Jilaihawi, H; Kim, WK; Kini, AS; Kofoed, KF; Leipsic, JA; Makkar, R; Mathiassen, ON; Mehran, R; Nørgaard, BL; Søndergaard, L; Terkelsen, CJ; Van Mieghem, N; Veien, KT; Windecker, S	1
Bowrin, K; Briere, JB; Cowie, MR; Cristeau, O; Lamy, A; Levy, P; Mealing, S; Mernagh, P; Millier, A	1
Brunetti, ND; Caldarola, P; De Gennaro, L; Di Biase, M	1
Liao, YWB; Wang, TKM	1
Carrero, JJ; Lazarus, B	1
Brusselaers, N; Fornes, R; Liu, Q; Simin, J	1
Di Leo, A; Leandro, G; Losurdo, G	1
Eikelboom, J; Moayyedi, P; Yusuf, S	1
Sugiyama, T	1
Berkowitz, SD; Chamorro, A; Demchuk, A; Hart, RG; Joensuu, H; Kasner, SE; Liu, YY; Marti-Fabregas, J; Martinez-Majander, N; Mundl, H; Ntaios, G; Perera, KS; Prats-Sanchez, L; Rudilosso, S; Saarinen, J; Tatlisumak, T; Themeles, E; Tiainen, M; Ylikotila, P	1
Aboyans, V; Anand, SS; Cowie, MR; Debus, ES; Fox, KAA; Gay, A; Lawatscheck, R; Monje, D; Vogtländer, K; Zeymer, U	1
Bafford, R; Cummings, C; Gonze, M; Gurbel, P; Mackrell, P; Rout, A; Sukhi, A; Tantry, U; Ulloa, K	1
De Luca, L	2
Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brodmann, M; Capell, WH; Debus, ES; Diao, L; Diaz, R; Fanelli, F; Gudz, I; Haskell, LP; Hess, CN; Hiatt, WR; Jaeger, N; Kittelson, JM; Krievins, DK; Mátyás, L; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR	1
Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Lewis, BS; Maggioni, AP; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Szarek, M; Verma, S; Widimský, P; Yusuf, S	1
Joore, M; Petersohn, S; Pouwels, X; Ramaekers, B; Ten Cate-Hoek, A	1
Anand, SS; Berkowitz, SD; Bosch, J; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Fox, KA; Guzik, TJ; Keller, L; Liang, Y; Liu, L; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Yusuf, S; Zhu, J	1
Berkowitz, SD; Connolly, SJ; Hart, RG; Kasner, SE; Korompoki, E; Milionis, H; Mundl, H; Ntaios, G; Pearce, LA; Sharma, M; Veltkamp, R	1
Dahly, D; Fleming, A; Kehoe, E; McGrath, B; Ní Cheallaigh, S; O'Byrne, JM; O'Connell, C; Sahm, LJ	1
Kanorskii, SG	1
Badariotti, G; Chahla, J; Perrotta, C; Ramos, J	2
Almendro-Delia, M; Bellmunt-Montoya, S; Cosín-Sales, J; García-Alegría, J; García-Moll, X; Gómez-Doblas, JJ; González-Juanatey, JR; Hernández, JL; Lozano, FS; Riambau, V; Suarez Fernández, C	1
Arnwine, C; Lockwood, K; Magness, JW; Reinert, A	1
Campbell, JD; McQueen, RB; Ollendorf, DA; Pearson, SD; Synnott, PG	1
Patti, G; Renda, G; Sticchi, A	1
Bhagirath, VC; Chan, NC; Díaz, R; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Shyamkumar, K; Sinha, S; Xu, K	1
Colivicchi, F; Cosentino, N; De Luca, L; Di Lenarda, A; Formigli, D; Gabrielli, D; Gulizia, MM; Meessen, J; Paolillo, C; Scherillo, M; Uguccioni, M	1
Angiolillo, DJ; Geisler, T; Heitmeier, S; Weitz, JI	1
Barbarash, OL; Kashtalap, VV	1
Gonzalez Della Valle, A; Liu, J; Memtsoudis, S; Nguyen, J; Salvati, EA; Shanaghan, KA; Sharrock, NE	1
Ameriso, SF; Arauz, A; Berkowitz, SD; Chamorro, Á; Connolly, SJ; Hankey, GJ; Hart, RG; Kasner, SE; Korompoki, E; Lindgren, A; Muir, KW; Mundl, H; Ozturk, S; Pearce, LA; Perera, K; Rudilosso, S; Sharma, M; Shoamanesh, A; Shuaib, A; Tatlisumak, T; Toni, D; Veltkamp, R	1
Aronow, HD; Chilton, RJ; Cigarroa, JE; Manning, PG; Sheikh, O; Vogt, JC	1
Berkowitz, SD; Czlonkowska, A; Endres, M; Krahn, T; Mundl, H; Nolte, CH; Pare, G; Peacock, WF; Pearce, LA; Scheitz, JF; Sharma, M; Shoamanesh, A	1
Arora, RC; Eikelboom, R; Lodewyks, C; Muller Moran, HR; Yan, W; Zelentsov, I	1
Bosch, J; Catanese, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, K; Perera, KS; Sharma, M; Shestakovska, O; Shoamanesh, A	1
Darius, H	1
Amarenco, P; Ameriso, SF; Bereczki, D; Berkowitz, SD; Connolly, SJ; Ferrari, J; Firstenfeld, A; Hart, RG; Kasner, SE; Lang, W; Lavados, P; Mikulik, R; Mundl, H; Ntaios, G; Pearce, LA; Perera, KS; Povedano, GP; Uchiyama, S; Yoon, BW	1
Hart, RG; Katsanos, AH	1
Eisen, A; Parascandolo, E	1
Abtan, J; Bhatt, DL; Billaut-Laden, I; Cacoub, P; Darmon, A; Ducrocq, G; Elbez, Y; Mas, JL; Montalescot, G; Steg, PG	1
Cauchon, M; Huard, G; Lanthier, L; Plourde, ME	1
Akeroyd, JM; Ballantyne, CM; Bhatt, DL; Hira, RS; Kataruka, A; Kazi, DS; Mahtta, D; Petersen, LA; Spertus, JA; Virani, SS	1
Gerstman, BB	1
Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T	1
Scott, LJ	1
Bell, JS; Chan, EW; Darzins, P; Fanning, L; Ilomaki, J; Lau, WCY; Leung, WK; Li, X; Man, KKC; Mongkhon, P; Wei, L; Wong, ICK	1
A A Fox, K; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Casanova, A; Connolly, SJ; Dagenais, GR; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Hart, RG; Keltai, K; Keltai, M; Kim, JH; Liang, Y; Liu, L; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; O'Donnell, M; Piegas, LS; Pogosova, N; Probstfield, JL; Reeh, KW; Ryden, L; Sharma, M; Smith, EE; Störk, S; Tonkin, AM; Varigos, JD; Vinereanu, D; Yusuf, S; Zhu, J	1
Souček, M; Šustr, F	1
Abola, MT; Aboyans, V; Anand, SS; Avezum, A; Bangdiwala, SI; Berkowitz, SD; Dyal, L; Eikelboom, JW; Fox, KAA; Kaplovitch, E; Verhamme, P; Yusuf, S	1
Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC	1
Kwon, O; Masic, D; Rech, MA	1
Berkowitz, SD; Connolly, SJ; Field, TS; Hart, RG; Kasner, SE; Liu, YY; Lutsep, H; Martí-Fàbregas, J; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Olavarria, V; Santo, GC; Sharma, M; Shoamanesh, A; Smith, EE; Uchiyama, S; Veltkamp, R	1
Anand, SS; Bauersachs, R; Berkowitz, SD; Bonaca, MP; Brackin, T; Brasil, D; Capell, WH; Debus, ES; Haskell, L; Hess, CN; Hiatt, WR; Jaeger, N; Madaric, J; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR; Sillesen, H; Szalay, D	1
Brouns, AE; Chayoua, W; Coenen, DM; Cosemans, JMEM; Debets, J; Heitmeier, S; Karel, MFA; Konings, J; Korsten, EIJ; Kuijpers, MJE; Leenders, PJA; Mastenbroek, TG; Nagy, M; Spronk, HM; van Essen, H; van Oerle, R	1
Schouten, O; Steunenberg, SL; Ultee, KHJ	1
Gremmel, T	1
Bauersachs, RM; Bonaca, MP; Hiatt, WR	1
Haruta, H; Hirayama, A; Hiro, T; Kitano, D; Kurosawa, T; Li, Y; Matsumoto, T; Migita, S; Mitsumata, M; Okumura, Y; Sudo, M; Takahashi, R; Takayama, T; Taniguchi, Y	1
Cho, HJ; Choi, HY; Choi, S; Jang, HJ; Jang, SS; Jeon, S; Kim, DE; Kim, H; Kim, J; Kim, K; Kim, YD; Kwon, IC; Lee, KY; Lee, SK; Nahrendorf, M; Ryu, WS; Schellingerhout, D	1
Farber, A	1
Barnes, GD	1
Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J	1
Fitzmaurice, G; McCaw, ZR; Wei, LJ	1
Fox, KAA	1
Cao, SL; Feng, B; Li, Z; Luo, T; Ren, Y; Weng, XS	1
Fonyakin, AV; Geraskina, LA	1
Dai, Z; Hu, B; Hu, M; Jiang, L; Tang, H; Yu, J	1
Costa, G; Gonçalves, L; Teixeira, R	1
Cortesi, PA; Di Laura, D; Ferrara, P; Maggioni, AP; Mantovani, LG	1
Ahlbrecht, S; Benkhoff, M; Dannenberg, L; Helten, C; Huhn-Wientgen, R; Kelm, M; Levkau, B; M'Pembele, R; Mourikis, P; Petzold, T; Polzin, A; Richter, H; Thienel, M; Zako, S; Zikeli, D	1
de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD	1
Grachev, VG; Smolenskaya, OG; Vedenskaya, SS	1
Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL	1
Kozieł, M; Lip, GY; Shantsila, E	1
Darmon, A; Ducrocq, G	1
Aboyans, V; Berkowitz, SD; Bhatt, DL; Bosch, JJ; Connolly, SJ; Dagenais, GR; Dyal, L; Eikelboom, JW; Fox, KAA; Leong, DP; Muehlhofer, E; Probstfield, JL; Widimsky, P; Winkelmann, BR; Yusuf, S	1
Cornett, B; Dziadkowiec, O; Harkness, W; Hassan, S; Hicks, ME; Kopstein, M; Scherbak, D; Watts, PJ	1
Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Leong, DP; Maggioni, AP; Muehlhofer, E; Shestakovska, O; Vanassche, T; Verhamme, P; Widimsky, P; Yusuf, S	1
Albers, GW; Bernstein, R; Brachmann, J; Camm, AJ; Fromm, P; Goto, S; Granger, CB; Hohnloser, SH; Hylek, E; Kowey, P; Krieger, D; Passman, R; Pines, JM	1
Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Félix, C; Fox, KAA; Guzik, TJ; Hart, RG; Maggioni, AP; Muehlhofer, E; Sharma, M; Shestakovska, O; Yusuf, S	1
Chen, H; Halperin, JL; Olin, JW	1
Akao, M; Ako, J; Fukaya, H; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamra, M; Ogawa, H; Yasuda, S	1
Camelo-Castillo, A; Esteve-Pastor, MA; Gil-Pérez, P; López-García, C; Marín, F; Orenes-Piñero, E; Ramírez-Macías, I; Rivera-Caravaca, JM; Tello-Montoliu, A	1
Aboyans, V; Bongard, V; Boulon, C; Bura-Rivière, A; Constans, J; Ferrières, J; Lacroix, P; Lapébie, FX; Messas, E	1
Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brackin, T; Capell, WH; Conte, M; Debus, ES; Fanelli, F; Govsyeyev, N; Haskell, LP; Hess, CN; Hiatt, WR; Hinterreiter, F; Jaeger, N; Krievins, D; Mills, J; Muehlhofer, E; Nault, P; Nehler, MR; Patel, MR; Piffaretti, G; Sillesen, HH; Svetlikov, A	1
Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Bracken, T; Capell, WH; Debus, SE; Haskell, LP; Hess, CN; Hiatt, WR; Hsia, J; Krantz, MJ; Krievins, DK; Mátyás, L; Muehlhofer, E; Nault, P; Nehler, MR; Patel, MR; Stefanov, S; Szarek, M	1
Ambler, GK; Behrendt, CA; Nordanstig, J; Twine, CP	1
Anand, SS; Bauersachs, R; Berkowitz, SD; Bonaca, MP; Branch, KRH; Debus, S; Dyal, L; Eikelboom, J; Fox, KAA; Haskell, LP; Hiatt, W; Liang, Y; Muehlhofer, E; Nehler, M; Patel, M; Szarek, M; Yusuf, S	1
Lip, GYH; Vallabhaneni, SR; Zhang, J	1
Maksimova, MY	1
Basili, S; Cangemi, R; Corica, B; Romiti, GF	1
Birkenfeld, AL; Bornstein, SR; Hanefeld, M; Henkel, E; Matschke, JB; Pistrosch, F; Schipp, B; Schipp, D; Sradnick, J; Weigmann, I	1
Bauersachs, R; Bowrin, K; Clay, E; Hawkins, N; Huelsebeck, M; Wojciechowski, P; Wu, O	1
Gong, ZB; Liang, Y; Liu, LS; Lou, KJ; Zhu, J	1
Ameriso, SF; Barlinn, J; Berkowitz, SD; Connolly, SJ; Coutts, SB; Damgaard, D; Hart, RG; Lambeck, J; Messé, SR; Modrau, B; Mundl, H; Pearce, LA; Perera, KS; Rha, JH; Romano, M; Saad, F; Sharma, M; Shoamanesh, A; Smith, EE; Yoon, BW	1
Harris, KC; Jefferies, JL; Justino, H; Li, JS; Lu, W; McCrindle, BW; Michelson, AD; Miriam Pina, L; Nessel, K; Pablo Sandoval, J; Peluso, C; Suzana Horowitz, E; Van Bergen, AH	1
Kotalczyk, A; Lip, GYH; Vallabhaneni, SR	1
Anand, SS; Bauersachs, RM; Beckman, JA; Berkowitz, SD; Bonaca, MP; Brodmann, M; Capell, WH; Debus, ES; Diaz, R; Habertheuer, P; Haskell, LP; Hess, CN; Hsia, J; Leeper, NJ; Muehlhofer, E; Nehler, MR; Patel, MR; Powell, RJ; Sillesen, H; Szarek, M	1
Baker, WL; Bookhart, B; Coleman, CI; Kharat, AA	1
Birnbaum, LA; Kamel, H; Kasner, SE; Merkler, AE; Pearce, LA; Sharma, R; Sheth, KN; Shoamanesh, A	1
Ameriso, SF; Bereczki, D; Berkowitz, SD; Damgaard, D; Engelter, ST; Fiebach, JB; Gagliardi, RJ; Hart, RG; Kasner, SE; Mikulik, R; Muir, KW; Mundl, H; O'Donnell, MJ; Pearce, LA; Perera, KS; Puig, J; Saad, F; Shamalov, N; Sharma, M; Shoamanesh, A; Smith, EE; Toni, DS; Veltkamp, RC; Yoon, BW	1
Grassl, KJ; Klocker, J; Moll, CW; Moll, MA; Neururer, SB; Westreicher, W; Wipper, SH; Zwerger, D	1
Eldrup, N; Larsen, TB; Nielsen, PB; Skjøth, F; Søgaard, M	1
Bosch, J; Canavan, M; Hart, RG; Mikulík, R; O'Donnell, MJ; Pearce, LA; Sharma, M; Whiteley, WN	1
Cook, HE; Hewitt, JH; Patterson, EP; Randolph, AE	1
Li, X; Wang, H; Wu, H; Wu, X; Xie, G	1
Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brasil, D; Brodmann, M; Capell, WH; Debus, ES; Diaz, R; Haskell, LP; Hess, CN; Hsia, J; Leeper, NJ; Mátyás, L; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M	1
Coughlin, T; Fleifil, SM; Grover, SP; Heitmeier, S; Mackman, N; Owens, AP; Posma, JJN; Spronk, HHM	1
Anand, SS; Chan, N; Kaplovitch, E; McClure, GR	1
Bosch, J; Canavan, M; Hart, RG; Mikulík, R; Mundl, H; O'Donnell, MJ; Pearce, LA; Sharma, M; Whiteley, WN; Yusuf, S	1
Angiolillo, DJ; Bass, TA; Been, L; Franchi, F; Galli, M; Geisler, T; Jaoude, PA; Jennings, LK; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X	1
Aboyans, V; Alings, M; Anand, SS; Avezum, A; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, KRH; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hori, M; Ibrahim, KS; Kakkar, A; Keltai, K; Keltai, M; Kim, JH; Lamy, A; Lanas, F; Leong, DP; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Muehlhofer, E; Neumann, C; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, JL; Rydén, L; Sharma, M; Steg, PG; Stoerk, S; Tasto, C; Tonkin, AM; Torp-Pedersen, C; Tyrwitt, J; Vanassche, T; Varigos, JD; Verhamme, P; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J	1
Amelin, AV; Arutyunov, GP; Fonyakin, AV; Khasanova, DR; Kulesh, AA; Maximova, MY; Mkrtchyan, VR; Putilina, MV; Sorokoumov, VA; Voznyuk, IA	1
Aboyans, V; Anand, SS; Bosch, J; Cowie, MR; Debus, ES; Fox, KAA; Gay, A; Patel, M; Vogtländer, K; Welsh, RC; Zeymer, U	1
Anand, SS; Bauersachs, RM; Baumgartner, I; Berkowitz, SD; Bonaca, MP; Capell, W; Debus, ES; Haskell, LP; Hess, CN; Hsia, J; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M	1
Alings, M; Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Muehlhofer, E; Pogosova, N; Shestakovska, O; Verhamme, P; Yusuf, S	1
Anand, SS; Bauersachs, RM; Beckman, JA; Berkowitz, SD; Bonaca, MP; Bura-Rivière, A; Capell, WH; Debus, ES; Haskell, LP; Henkin, S; Hess, CN; Hsia, J; Lawall, H; Muehlhofer, E; Nehler, MR; Patel, MR; Piazza, G; Roztocil, K; Szarek, M	1
de Borst, GJ; Kappelle, LJ; Nugteren, MJ; Ten Berg, JM; Ünlü, Ç; van den Broek, WWA	1
Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J	1
Ding, Q; Yan, S; Yue, QY; Zhang, Q	1
Aboalhasan, E; Abu-Dogosh, A; Abu-Salman, A; Alnsasra, H; Arbel, R; Azuri, J; Barrett, O; El Nasasra, A; Golan, YB; Hammerman, A; Tsaban, G; Weissberg, I; Westreich, R	1
Aynardi, MC; Bonaddio, V; Kirchner, GJ; Koroneos, Z; Lorenz, FJ; Manto, KM; Martinazzi, BJ; Stauch, CM	1
Goto, S	1
Alves, M; Rodrigues Lopes, A; Rosado Julião, S	1
de Borst, GJ; Hannink, G; Kramers, K; Maas, DPMSM; Mees, BME; Reijnen, MMPJ; Riksen, NP; Ten Cate, H; van der Vijver-Coppen, RJ; Warlé, MC; Willems, LH; Zeebregts, CJ	1
Aboyans, V; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, S; Dagenais, GR; Durand-Zaleski, I; Eikelboom, J; Ertl, G; Lamy, A; Lonn, E; Probstfield, J; Ryden, L; Steg, PG; Störk, S; Tong, W; Wang, WJ; Yuan, F; Yusuf, S	1
Adik-Pathak, L; Gupta, A; Shirodkar, S	1
Eikelboom, JW; Hart, RG; Katsanos, AH; Perera, KS	1
Almas, A; Anand, SS; Avezum, A; Bangdiwala, SI; Belley-Cote, EP; Berwanger, O; Bosch, J; Choudhri, S; Diaz, R; Drapkina, O; Eikelboom, JW; Farkouh, ME; Felix, C; Harper, W; Hassany, M; Heenan, L; Jolly, SS; Kumar Sharma, S; Loeb, M; Lopes, RD; Lopez-Jaramillo, P; Luz Diaz, M; Rangarajan, S; Tarhuni, WM; Wasserman, S; Whitlock, RP; Xu, L; Yusuf, S; Yusufali, A	1
Qiu, Y; Wang, Y; Xing, Y; Yang, L; Yuan, Z	1
Kanny, O; Khan, H; Qadura, M; Syed, MH	1
Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Debus, ES; Haskell, LP; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M	1
Ababneh, M; Abedalqader, NN; Rababa'h, AM	1
Bhatt, DL; Bosch, J; Dagenais, GR; Eikelboom, JW; Fox, KAA; Gaba, P; Leong, D; Maggioni, AP; Widimsky, P; Yusuf, S	1
Angiolillo, DJ; D'Amario, D; De Caterina, R; Franchi, F; Galli, M; Gibson, CM; Mehran, R; Ortega-Paz, L; Rollini, F	1
Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Capell, WH; Chung, J; Conte, MS; Debus, S; Dorigo, W; Govsyeyev, N; Gudz, I; Haskell, LP; Hess, CN; Jaeger, N; Krievins, D; Mills, J; Moll, F; Muehlhofer, E; Nehler, M; Norgren, L; Patel, MR; Piffaretti, G; Powell, R; Sillesen, H; Szalay, D; Szarek, M; Wohlauer, M	1
Altamura, V; Bianco, M; Caldarola, P; Ceravolo, R; Cipriani, M; Colivicchi, F; De Luca, L; Di Fusco, SA; Francese, GM; Gabrielli, D; Gulizia, MM; Lucà, F; Nardi, F; Navazio, A; Oliva, F; Riccio, C; Rizzello, V; Scicchitano, P; Valente, S	1
Abdel-Qadir, H; Chu, A; Farkouh, ME; Ferreira-Legere, LE; Goodman, SG; Ko, DT; Porter, J; Sheth, MS; Tam, DY; Udell, JA; Yu, B	1
Erika, MH; Jaime, GC; Maximiliano, CL	1
Budaj, A; Carlin, S; de Vries, TAC; Eikelboom, J	1
Attena, E; Cotticelli, C; D'Alterio, G; D'Onofrio, A; Fabiani, D; Golino, P; Leonardi, S; Maione, B; Nigro, G; Rago, A; Russo, V; Sarpa, S	1
Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Eikelboom, JW; Maggioni, AP; Muehlhofer, E; Probstfield, JL; Shestakovska, O; Widimsky, P; Yi, Q; Yusuf, S	1
Bangdiwala, SI; Belanger, J; Bosch, J; Connolly, S; Dagenais, GR; Dyal, L; Eikelboom, J; Marsden, T; Renters, M; Swaminathan, B; Tang, C; Yuan, F	1
Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C	1
Christ, AB; Heckmann, ND; Kang, HP; Lieberman, JR; Mayfield, CK; Mills, ES; Piple, AS; Wang, JC	1
Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J	1
Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S	1
Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T	1
Aboyans, V; Anand, S; Bosch, J; Connolly, S; Eikelboom, J; Muehlhofer, E; Qadura, M; Syed, MH; Yusuf, S	1
Ito, Y; Kimata, M; Koseki, T; Sekido, K; Tanaka, J; Yamada, S	1
Bu, Y; Jia, X; Li, J; Ma, S; Qiu, M; Wang, X; Zhang, L; Zhou, T	1
Cai, Y; Chen, Z; He, Y; Li, C; Zhang, J	1
Liu, C; Ma, L	1

Reviews

78 review(s) available for aspirin and rivaroxaban

Article	Year
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clinical orthopaedics and related research, 2008, Volume: 466, Issue:3 Topics: Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Azetidines; Benzylamines; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin	2008
VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients. Thrombosis research, 2010, Volume: 125 Suppl 2 Topics: Anticoagulants; Aspirin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin	2010
Clot prevention--common questions about medications. Australian family physician, 2010, Volume: 39, Issue:7 Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; International Normalized Ratio; Morpholines; Pharmacogenetics; Pyridines; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism	2010
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1 Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin	2012
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin	2012
The management of antithrombotic medication in skin surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2012, Volume: 38, Issue:9 Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin	2012
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations. Injury, 2013, Volume: 44, Issue:12 Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism	2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clinical therapeutics, 2013, Volume: 35, Issue:7 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2013
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.), 2013, Aug-30, Volume: 347 Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K	2013
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. The journal of trauma and acute care surgery, 2013, Volume: 75, Issue:3 Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin	2013
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. European journal of internal medicine, 2014, Volume: 25, Issue:1 Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin	2014
Anticoagulation and antiplatelet therapy in acute coronary syndromes. Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2014
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine	2014
[More with atrial fibrillation, anticoagulants since the coming of NOAK ]. Lakartidningen, 2015, Jan-06, Volume: 112 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin	2015
[Anticoagulant therapy in secondary prevention of coronary events]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin	2014
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6 Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopidogrel; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Lactones; Male; Mice; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Factors; Species Specificity; Ticagrelor; Ticlopidine; Time Factors	2015
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation. Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:12 Suppl 2 Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; Hemorrhage; Humans; Ligation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Warfarin	2015
A systematic review of anti-thrombotic therapy in epistaxis. Rhinology, 2016, 12-01, Volume: 54, Issue:4 Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Clopidogrel; Dabigatran; Disease Management; Epistaxis; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Ticlopidine; Tranexamic Acid; Warfarin	2016
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. The Journal of arthroplasty, 2017, Volume: 32, Issue:9 Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin	2017
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. The Cochrane database of systematic reviews, 2017, 12-15, Volume: 12 Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; Stroke; Venous Thromboembolism; Warfarin	2017
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 02-01, Volume: 34, Issue:2 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2019
Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding. BMJ evidence-based medicine, 2018, Volume: 23, Issue:5 Topics: Aspirin; Carotid Artery Diseases; Double-Blind Method; Hemorrhage; Humans; Rivaroxaban	2018
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. Critical pathways in cardiology, 2018, Volume: 17, Issue:2 Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Histones; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombosis; Warfarin	2018
[Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)]. Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:15 Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Germany; Guideline Adherence; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Postoperative Care; Rivaroxaban; Secondary Prevention; Ticlopidine; Veins	2018
Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice? Thrombosis and haemostasis, 2018, Volume: 118, Issue:9 Topics: Acute Coronary Syndrome; Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Rivaroxaban	2018
Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis. JAMA neurology, 2018, 12-01, Volume: 75, Issue:12 Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridones; Rivaroxaban	2018
Triple therapy: worth the risk? Minerva medica, 2018, Volume: 109, Issue:5 Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Mortality; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Rivaroxaban; Stents; Stroke; Thrombophilia; Ticlopidine	2018
Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial. Current pharmaceutical design, 2018, Volume: 24, Issue:38 Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome	2018
Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:4 Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2019
Antithrombotic Agents. Circulation research, 2019, Volume: 124, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Factor XI; Factor XII; Hemorrhage; Humans; Peripheral Arterial Disease; Plaque, Atherosclerotic; Platelet Aggregation; Platelet Aggregation Inhibitors; Primary Prevention; Risk Assessment; Rivaroxaban; Secondary Prevention; Thrombin; Thrombosis; Venous Thrombosis	2019
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thrombosis and haemostasis, 2019, Volume: 119, Issue:4 Topics: Aged; Anticoagulants; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Risk; Rivaroxaban	2019
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. Thrombosis and haemostasis, 2019, Volume: 119, Issue:5 Topics: Anticoagulants; Aspirin; Canada; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Recurrence; Risk; Rivaroxaban; Treatment Outcome; Venous Thromboembolism	2019
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? Thrombosis and haemostasis, 2019, Volume: 119, Issue:10 Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Decision Making; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Rivaroxaban; Secondary Prevention; Stroke; Ticagrelor	2019
Rivaroxaban and the EINSTEIN clinical trial programme. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2019, Volume: 30, Issue:3 Topics: Adult; Aspirin; Child; Clinical Trials as Topic; Humans; Precision Medicine; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Venous Thromboembolism; Venous Thrombosis	2019
Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. Clinical drug investigation, 2019, Volume: 39, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2019
Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review. Current cardiology reports, 2019, 05-18, Volume: 21, Issue:7 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2019
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Kardiologia polska, 2019, Aug-23, Volume: 77, Issue:7-8 Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban	2019
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. Blood transfusion = Trasfusione del sangue, 2020, Volume: 18, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Vitamin K	2020
Does the form of venous thromboembolism prophylaxis following primary total knee arthroplasty alter the rate of early reoperation or revision surgery? ANZ journal of surgery, 2019, Volume: 89, Issue:10 Topics: Arthroplasty, Replacement, Knee; Aspirin; Australia; Case-Control Studies; Clinical Decision-Making; Enoxaparin; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Perioperative Period; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Reoperation; Rivaroxaban; Safety; Treatment Outcome; Venous Thromboembolism	2019
Role of rivaroxaban in the prevention of atherosclerotic events. Expert review of clinical pharmacology, 2019, Volume: 12, Issue:8 Topics: Animals; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Secondary Prevention	2019
Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients. Thrombosis and haemostasis, 2019, Volume: 119, Issue:9 Topics: Administration, Oral; Anticoagulants; Aspirin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2019
Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, Volume: 22, Issue:8 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Bayes Theorem; Cost-Benefit Analysis; Elective Surgical Procedures; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Patient Preference; Pulmonary Embolism; Risk Assessment; Rivaroxaban; Venous Thromboembolism	2019
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios. Current cardiology reports, 2019, 08-30, Volume: 21, Issue:10 Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombolytic Therapy	2019
Venous thromboembolism in plastic surgery: the current state of evidence in risk assessment and chemoprophylactic options. Journal of plastic surgery and hand surgery, 2019, Volume: 53, Issue:6 Topics: Administration, Oral; Anticoagulants; Aspirin; Chemoprevention; Heparin, Low-Molecular-Weight; Humans; Incidence; Plastic Surgery Procedures; Postoperative Complications; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Venous Thromboembolism	2019
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. Thrombosis research, 2019, Volume: 184 Topics: Aspirin; Cardiovascular Diseases; Factor Xa Inhibitors; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban	2019
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials. Coronary artery disease, 2020, Volume: 31, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin	2020
[Antithrombotic therapy after acute coronary syndromes: is it possible to identify the PEGASUS and COMPASS patient?] Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:2 Suppl 1 Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Humans; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Time Factors	2020
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. The Cochrane database of systematic reviews, 2020, 05-06, Volume: 5 Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Knee Joint; Postoperative Complications; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Stockings, Compression; Venous Thrombosis	2020
Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. Expert review of clinical pharmacology, 2020, Volume: 13, Issue:7 Topics: Aspirin; Chronic Disease; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hospitalization; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Syndrome	2020
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:6 Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Eicosapentaenoic Acid; Hemorrhage; Humans; Models, Economic; Randomized Controlled Trials as Topic; Rivaroxaban; Time Factors; Treatment Outcome	2020
Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety? Future cardiology, 2021, Volume: 17, Issue:1 Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2021
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and haemostasis, 2020, Volume: 120, Issue:8 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Forecasting; Hemorrhage; Humans; Peripheral Arterial Disease; Platelet Activation; Platelet Aggregation Inhibitors; Recurrence; Rivaroxaban; Secondary Prevention; Thrombin	2020
[Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?] Terapevticheskii arkhiv, 2019, Dec-15, Volume: 91, Issue:12 Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Rivaroxaban	2019
The COMPASS trial: practical considerations for application after coronary artery bypass surgery. Current opinion in cardiology, 2020, Volume: 35, Issue:5 Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Treatment Outcome	2020
Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis. Neurology, 2020, 08-04, Volume: 95, Issue:5 Topics: Aged; Aspirin; Atherosclerosis; Factor Xa Inhibitors; Female; Hematoma, Subdural, Intracranial; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban	2020
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. JAMA neurology, 2020, 10-01, Volume: 77, Issue:10 Topics: Anti-Inflammatory Agents; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Fibrinolytic Agents; Humans; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke	2020
Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review. Expert review of cardiovascular therapy, 2020, Volume: 18, Issue:9 Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2020
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, Volume: 80, Issue:14 Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Rivaroxaban; Secondary Prevention	2020
[The new Epoch of Antithrombotic Therapy in the Long-Term Prevention of a non-Cardioembolic Stroke]. Kardiologiia, 2021, Jan-19, Volume: 60, Issue:12 Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Stroke	2021
Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis. Journal of orthopaedic surgery and research, 2021, Feb-13, Volume: 16, Issue:1 Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Female; Fracture Fixation, Internal; Hip Fractures; Humans; Male; Middle Aged; Postoperative Complications; Rivaroxaban; Treatment Outcome; Venous Thromboembolism	2021
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:3 Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Lower Extremity; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban	2021
Anticoagulation versus placebo for heart failure in sinus rhythm. The Cochrane database of systematic reviews, 2021, 05-18, Volume: 5 Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Chronic Disease; Heart Failure; Heart Rate; Hemorrhage; Humans; Placebo Effect; Placebos; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thromboembolism; Warfarin	2021
Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke, 2021, Volume: 52, Issue:8 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Clinical Trials as Topic; Dual Anti-Platelet Therapy; Embolic Stroke; Factor Xa Inhibitors; Humans; Intracranial Embolism; Rivaroxaban; Secondary Prevention	2021
Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International journal of molecular sciences, 2021, Jul-01, Volume: 22, Issue:13 Topics: Anticoagulants; Aspirin; Blood Coagulation; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombolytic Therapy; Thrombosis	2021
Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2021, Volume: 62, Issue:4 Topics: Aged; Aspirin; Clopidogrel; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Lower Extremity; Male; Middle Aged; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome	2021
Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis. Cardiovascular therapeutics, 2021, Volume: 2021 Topics: Adult; Aspirin; Humans; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2021
Review new concepts in pharmacotherapy for peripheral arterial disease. Current opinion in cardiology, 2021, 11-01, Volume: 36, Issue:6 Topics: Aspirin; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2021
Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. Current medical research and opinion, 2022, Volume: 38, Issue:1 Topics: Adult; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban	2022
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. The Canadian journal of cardiology, 2022, Volume: 38, Issue:5 Topics: Aspirin; Canada; Clinical Decision-Making; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Assessment; Rivaroxaban	2022
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. The Cochrane database of systematic reviews, 2022, 08-22, Volume: 8 Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pain; Pulmonary Embolism; Rivaroxaban; Venous Thromboembolism	2022
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs, 2022, Volume: 82, Issue:12 Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor; Vitamin K	2022
Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. International journal of molecular sciences, 2022, Sep-26, Volume: 23, Issue:19 Topics: Anticoagulants; Aspirin; Clopidogrel; Factor X; Humans; Platelet Aggregation Inhibitors; Point-of-Care Testing; Rivaroxaban; Ticagrelor; Vascular Diseases	2022
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications. Expert review of clinical pharmacology, 2023, Volume: 16, Issue:1 Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2023
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023, Volume: 23, Issue:3 Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Regression Analysis; Rivaroxaban; Stroke; Ticagrelor	2023
Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. Cardiovascular therapeutics, 2023, Volume: 2023 Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Humans; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor	2023
Who may benefit from low-dose rivaroxaban plus aspirin? Practical implications for outpatients with cardiovascular disease. Polish archives of internal medicine, 2023, 10-26, Volume: 133, Issue:10 Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Ischemia; Outpatients; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2023
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Medicine, 2023, Dec-01, Volume: 102, Issue:48 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Treatment Outcome	2023

Trials

112 trial(s) available for aspirin and rivaroxaban

Article	Year
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. Journal of clinical pharmacology, 2006, Volume: 46, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Antithrombin III; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Male; Middle Aged; Molecular Structure; Morpholines; Platelet Aggregation; Rivaroxaban; Thiophenes	2006
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683 Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome	2009
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis research, 2012, Volume: 130, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Interactions; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Effects on platelet function of a direct acting antagonist of coagulation factor Xa. Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:3 Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Crotalid Venoms; Factor Xa; Factor Xa Inhibitors; Female; Humans; Lectins, C-Type; Male; Middle Aged; Morpholines; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rivaroxaban; Thiophenes	2012
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology, 2013, Jul-23, Volume: 62, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stents; Thiophenes; Thrombosis; Treatment Outcome	2013
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thrombosis research, 2013, Volume: 132, Issue:2 Topics: Adolescent; Adult; Animals; Anticoagulants; Aspirin; Cross-Over Studies; Female; Humans; In Vitro Techniques; Male; Middle Aged; Morpholines; Platelet Aggregation; Rivaroxaban; Swine; Thiophenes; Thrombosis; Venous Thromboembolism; Young Adult	2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clinical therapeutics, 2013, Volume: 35, Issue:7 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European heart journal, 2014, Volume: 35, Issue:4 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2014
Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:7 Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Thiophenes; Venous Thrombosis	2014
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:11 Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult	2014
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thrombosis and haemostasis, 2015, Aug-31, Volume: 114, Issue:3 Topics: Aspirin; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Recurrence; Research Design; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism	2015
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemporary clinical trials, 2015, Volume: 43 Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Research Design; Rivaroxaban; Ticagrelor; Ticlopidine; Warfarin	2015
Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial. BMC neurology, 2015, Oct-12, Volume: 15 Topics: Adult; Aspirin; Clinical Protocols; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient; Male; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Recurrence; Rivaroxaban; Stroke	2015
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American heart journal, 2016, Volume: 174 Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult	2016
Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia. Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 2016, Volume: 26, Issue:4 Topics: Administration, Oral; Anemia, Hemolytic, Autoimmune; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; California; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Male; Prospective Studies; Rivaroxaban; Treatment Outcome; Washington	2016
Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study. Scientific reports, 2016, 06-22, Volume: 6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Aspirin; Catheter Ablation; China; Female; Femoral Vein; Humans; Lower Extremity; Male; Middle Aged; Prospective Studies; Rivaroxaban; Treatment Outcome; Venous Thrombosis; Young Adult	2016
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American heart journal, 2017, Volume: 184 Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, Combination; Embolism; Factor Xa Inhibitors; Heart Valve Diseases; Humans; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Pulmonary Embolism; Rivaroxaban; Stroke; Thrombosis; Ticlopidine; Transcatheter Aortic Valve Replacement; Venous Thrombosis	2017
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. The New England journal of medicine, 2017, 03-30, Volume: 376, Issue:13 Topics: Adult; Aged; Aspirin; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Venous Thromboembolism	2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet (London, England), 2017, May-06, Volume: 389, Issue:10081 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Praxis, 2017, Volume: 106, Issue:13 Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Rivaroxaban; Secondary Prevention; Treatment Outcome; Venous Thromboembolism	2017
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England journal of medicine, 2017, 10-05, Volume: 377, Issue:14 Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2017
[The EINSTEIN CHOICE study]. Giornale italiano di cardiologia (2006), 2017, Volume: 18, Issue:9 Topics: Aspirin; Double-Blind Method; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Rivaroxaban; Venous Thromboembolism	2017
[EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2017, Volume: 45, Issue:Suppl 4 Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Rivaroxaban; Treatment Outcome; Venous Thromboembolism	2017
[After the GEMINI-ACS-1 trial]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2017, Volume: 45, Issue:Suppl 4 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Humans; Rivaroxaban; Thrombosis	2017
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117 Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morbidity; Myocardial Infarction; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke	2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117 Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Lower Extremity; Male; Middle Aged; Morbidity; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke	2018
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. American heart journal, 2018, Volume: 197 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke	2018
[The COMPASS study]. Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:1 Topics: Aspirin; Atherosclerosis; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Follow-Up Studies; Humans; Rivaroxaban; Treatment Outcome; Vascular Diseases	2018
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. The New England journal of medicine, 2018, 02-22, Volume: 378, Issue:8 Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Factors; Rivaroxaban; Venous Thromboembolism	2018
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Comorbidity; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Racial Groups; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Treatment Outcome	2018
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. Journal of the American College of Cardiology, 2018, 05-22, Volume: 71, Issue:20 Topics: Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Lower Extremity; Male; Middle Aged; Mortality; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2018
Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood advances, 2018, 04-10, Volume: 2, Issue:7 Topics: Adult; Aged; Aspirin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Venous Thromboembolism	2018
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). American heart journal, 2018, Volume: 199 Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endovascular Procedures; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Treatment Outcome	2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. The New England journal of medicine, 2018, Jun-07, Volume: 378, Issue:23 Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Embolism; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Stroke	2018
Praxis, 2018, Volume: 107, Issue:12 Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; Equivalence Trials as Topic; Female; Humans; Male; Middle Aged; Postoperative Complications; Rivaroxaban; Venous Thromboembolism	2018
Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study. PloS one, 2018, Volume: 13, Issue:8 Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Middle Aged; Norway; Pharmacoepidemiology; Risk Factors; Rivaroxaban; Thrombosis; Warfarin	2018
Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. International journal of cardiology, 2018, Nov-01, Volume: 270 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Markov Chains; Middle Aged; Rivaroxaban	2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. The Lancet. Neurology, 2018, Volume: 17, Issue:12 Topics: Aged; Aspirin; Cohort Studies; Double-Blind Method; Factor Xa Inhibitors; Female; Foramen Ovale, Patent; Humans; International Cooperation; Male; MEDLINE; Middle Aged; Platelet Aggregation Inhibitors; Rivaroxaban; Statistics, Nonparametric; Stroke; Treatment Outcome	2018
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. International journal of cardiology, 2019, Mar-01, Volume: 278 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Population Surveillance; Registries; Rivaroxaban	2019
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. Journal of the American College of Cardiology, 2019, 01-22, Volume: 73, Issue:2 Topics: Aged; Aspirin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Rivaroxaban; Treatment Outcome	2019
Stroke Outcomes in the COMPASS Trial. Circulation, 2019, 02-26, Volume: 139, Issue:9 Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Risk Factors; Rivaroxaban; Stroke	2019
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circulation research, 2019, Volume: 124, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Recurrence; Research Design; Rivaroxaban; Secondary Prevention; Stroke	2019
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA neurology, 2019, 07-01, Volume: 76, Issue:7 Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Intracranial Embolism; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Treatment Outcome	2019
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. JAMA cardiology, 2019, 06-01, Volume: 4, Issue:6 Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Heart Failure; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pulmonary Embolism; Rivaroxaban; Stroke; Stroke Volume; Thienopyridines; Thromboembolism; Venous Thrombosis	2019
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, Volume: 157, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rivaroxaban; Treatment Outcome	2019
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. Journal of the American College of Cardiology, 2019, 05-14, Volume: 73, Issue:18 Topics: Aged; Aspirin; Coronary Artery Disease; Correlation of Data; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Risk Adjustment; Rivaroxaban	2019
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). American heart journal, 2019, Volume: 213 Topics: Aspirin; Child; Child, Preschool; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Fontan Procedure; Humans; Male; Multicenter Studies as Topic; Postoperative Complications; Prospective Studies; Randomized Controlled Trials as Topic; Rivaroxaban; Thrombosis	2019
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA cardiology, 2019, 07-01, Volume: 4, Issue:7 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor	2019
Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. Journal of the American College of Cardiology, 2019, 06-04, Volume: 73, Issue:21 Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban	2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 2019, Volume: 157, Issue:3 Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocolitis, Pseudomembranous; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pantoprazole; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome	2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:8 Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Intracranial Embolism; Male; Middle Aged; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome	2019
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation, 2019, 08-13, Volume: 140, Issue:7 Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Heart Failure; Humans; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2019
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology, 2019, 07-02, Volume: 73, Issue:25 Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Risk Assessment; Rivaroxaban	2019
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke, 2019, Volume: 50, Issue:9 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery Diseases; Double-Blind Method; Factor Xa Inhibitors; Follow-Up Studies; Humans; Intracranial Embolism; Middle Aged; Rivaroxaban; Stroke; Treatment Outcome	2019
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. The New England journal of medicine, 2019, 09-19, Volume: 381, Issue:12 Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Rivaroxaban	2019
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European heart journal, 2019, 12-07, Volume: 40, Issue:46 Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Assessment; Rivaroxaban; Stroke	2019
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation, 2019, 10-29, Volume: 140, Issue:18 Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Neoplasms; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke	2019
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. JAMA neurology, 2020, 01-01, Volume: 77, Issue:1 Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Carotid Stenosis; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Heart Diseases; Humans; Intracranial Embolism; Rivaroxaban; Stroke	2020
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke, 2019, Volume: 50, Issue:11 Topics: Aged; Aorta, Thoracic; Aspirin; Atherosclerosis; Double-Blind Method; Echocardiography, Transesophageal; Female; Humans; Intracranial Embolism; Male; Middle Aged; Prevalence; Risk Factors; Rivaroxaban; Stroke	2019
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology, 2019, 09-24, Volume: 74, Issue:12 Topics: Aged; Aspirin; Coronary Artery Disease; Drug Combinations; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Severity of Illness Index	2019
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European journal of preventive cardiology, 2020, Volume: 27, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Heart Disease Risk Factors; Humans; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Assessment; Rivaroxaban; Secondary Prevention; Time Factors; Treatment Outcome	2020
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. The New England journal of medicine, 2020, 01-09, Volume: 382, Issue:2 Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Thromboembolism; Transcatheter Aortic Valve Replacement	2020
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. The New England journal of medicine, 2020, 01-09, Volume: 382, Issue:2 Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Four-Dimensional Computed Tomography; Heart Valve Prosthesis; Hemorrhage; Humans; Intention to Treat Analysis; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Thromboembolism; Transcatheter Aortic Valve Replacement	2020
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. European journal of neurology, 2020, Volume: 27, Issue:5 Topics: Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Humans; Intracranial Embolism; Ischemic Stroke; Neoplasms; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2020
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic even American heart journal, 2020, Volume: 222 Topics: Aspirin; Atherosclerosis; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Rivaroxaban; Treatment Outcome	2020
Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. Future cardiology, 2020, Volume: 16, Issue:2 Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Inflammation; Male; Peripheral Arterial Disease; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban	2020
Rivaroxaban in Peripheral Artery Disease after Revascularization. The New England journal of medicine, 2020, 05-21, Volume: 382, Issue:21 Topics: Aged; Aspirin; Cardiovascular Diseases; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Endovascular Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Ischemia; Kaplan-Meier Estimate; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation, 2020, 06-09, Volume: 141, Issue:23 Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Rivaroxaban	2020
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Cardiovascular research, 2021, 02-22, Volume: 117, Issue:3 Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Health Status Disparities; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Time Factors; Treatment Outcome	2021
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. Stroke, 2020, Volume: 51, Issue:6 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Disease-Free Survival; Double-Blind Method; Female; Humans; Intracranial Embolism; Male; Middle Aged; Platelet Aggregation Inhibitors; Prevalence; Risk Factors; Rivaroxaban; Stroke; Survival Rate	2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. JAMA neurology, 2020, 10-01, Volume: 77, Issue:10 Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Rivaroxaban	2020
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke, 2020, Volume: 51, Issue:8 Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Internationality; Intracranial Embolism; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Rivaroxaban; Stroke; Troponin T	2020
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:8 Topics: Aged; Aspirin; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intracranial Arteriosclerosis; Intracranial Embolism; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prevalence; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome	2020
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Budgets; Cardiovascular Diseases; Cigarette Smoking; Cross-Sectional Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Rivaroxaban; United States; United States Department of Veterans Affairs	2021
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA cardiology, 2021, 01-01, Volume: 6, Issue:1 Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double-Blind Method; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prognosis; Renal Insufficiency; Rivaroxaban; Severity of Illness Index; Stroke	2021
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. American heart journal, 2021, Volume: 231 Topics: Administration, Oral; Aspirin; Atrial Fibrillation; Atrial Flutter; Bioprosthesis; Brazil; Cause of Death; Creatinine; Embolism; Factor Xa Inhibitors; Heart Valve Prosthesis; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Mitral Valve; Rivaroxaban; Sample Size; Stroke; Surgical Procedures, Operative; Thrombosis; Treatment Outcome; Warfarin	2021
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA neurology, 2021, 01-01, Volume: 78, Issue:1 Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Humans; Male; Middle Aged; Prevalence; Recurrence; Rivaroxaban	2021
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation, 2020, 12-08, Volume: 142, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Internationality; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Treatment Outcome	2020
Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. Chinese medical journal, 2021, 01-05, Volume: 134, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Rivaroxaban; Venous Thromboembolism	2021
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. American heart journal, 2021, Volume: 236 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Adjustment; Rivaroxaban; Stroke	2021
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart (British Cardiac Society), 2021, Volume: 107, Issue:14 Topics: Aged; Aspirin; Coronary Disease; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Duration of Therapy; Female; Fibrinolytic Agents; Humans; Ischemic Stroke; Male; Mortality; Myocardial Infarction; Outcome and Process Assessment, Health Care; Peripheral Arterial Disease; Rivaroxaban; Withholding Treatment	2021
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European heart journal. Cardiovascular pharmacotherapy, 2022, 08-11, Volume: 8, Issue:5 Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Multimorbidity; Rivaroxaban	2022
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 07-06, Volume: 78, Issue:1 Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Heart Failure; Humans; Male; Outcome Assessment, Health Care; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Rivaroxaban; Severity of Illness Index	2021
Aspirin versus P2Y Heart (British Cardiac Society), 2021, Volume: 107, Issue:21 Topics: Aged; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombosis; Treatment Outcome	2021
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation, 2021, 10-05, Volume: 144, Issue:14 Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; Rivaroxaban	2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. European heart journal, 2021, 10-14, Volume: 42, Issue:39 Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke	2021
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. Diabetologia, 2021, Volume: 64, Issue:12 Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Cell-Derived Microparticles; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Pulse Wave Analysis; Risk Factors; Rivaroxaban	2021
[Rivaroxaban with aspirin for the secondary prevention of cardiovascular events in Chinese patients with stable cardiovascular diseases: subgroup analysis of COMPASS]. Zhonghua xin xue guan bing za zhi, 2021, Sep-24, Volume: 49, Issue:9 Topics: Aged; Aspirin; Cardiovascular Diseases; China; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban; Secondary Prevention	2021
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. Stroke, 2022, Volume: 53, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Infarction; Cohort Studies; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Internationality; Intracranial Embolism; Magnetic Resonance Imaging; Male; Middle Aged; Rivaroxaban; Stroke	2022
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. Journal of the American Heart Association, 2021, 11-16, Volume: 10, Issue:22 Topics: Anticoagulants; Aspirin; Child; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Stroke; Thrombosis; Venous Thromboembolism	2021
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation, 2021, 12-07, Volume: 144, Issue:23 Topics: Acute Disease; Aged; Aspirin; Female; Humans; Ischemia; Lower Extremity; Male; Middle Aged; Numbers Needed To Treat; Rivaroxaban	2021
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA neurology, 2021, 12-01, Volume: 78, Issue:12 Topics: Adult; Aged; Aspirin; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Rivaroxaban; Secondary Prevention; Ventricular Dysfunction, Left	2021
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. International journal of stroke : official journal of the International Stroke Society, 2022, Volume: 17, Issue:7 Topics: Aged; Aspirin; Brain Infarction; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Humans; Intracranial Embolism; Magnetic Resonance Imaging; Male; Prospective Studies; Rivaroxaban; Stroke	2022
Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022, Volume: 31, Issue:4 Topics: Activities of Daily Living; Aged; Aspirin; Female; Humans; Male; Rivaroxaban; Stroke	2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of thrombosis and haemostasis : JTH, 2022, Volume: 20, Issue:5 Topics: Anticoagulants; Arteries; Aspirin; Endovascular Procedures; Humans; Lower Extremity; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombosis	2022
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022, Volume: 31, Issue:5 Topics: Activities of Daily Living; Aspirin; Cognition; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Humans; Intracranial Embolism; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke	2022
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European heart journal. Cardiovascular pharmacotherapy, 2022, 12-02, Volume: 8, Issue:8 Topics: Aspirin; Drug Therapy, Combination; Humans; Infant; Myocardial Infarction; Peripheral Arterial Disease; Rivaroxaban; Stroke	2022
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. European heart journal. Cardiovascular pharmacotherapy, 2022, 12-02, Volume: 8, Issue:8 Topics: Aged; Aspirin; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Peripheral Arterial Disease; Registries; Rivaroxaban	2022
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association, 2022, 06-21, Volume: 11, Issue:12 Topics: Arteries; Aspirin; Endovascular Procedures; Female; Hemorrhage; Humans; Lower Extremity; Male; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Treatment Outcome	2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA network open, 2022, 06-01, Volume: 5, Issue:6 Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Lower Extremity; Male; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Venous Thromboembolism	2022
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. European heart journal, 2022, 10-07, Volume: 43, Issue:37 Topics: Asian People; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Peripheral Arterial Disease; Rivaroxaban	2022
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European heart journal. Quality of care & clinical outcomes, 2023, 08-07, Volume: 9, Issue:5 Topics: Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban	2023
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet. Respiratory medicine, 2022, Volume: 10, Issue:12 Topics: Adolescent; Adult; Aspirin; Canada; Colchicine; COVID-19 Drug Treatment; Disease Progression; Humans; Oxygen; Rivaroxaban; Treatment Outcome	2022
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. Clinical cardiology, 2022, Volume: 45, Issue:12 Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Tissue Plasminogen Activator; Treatment Outcome	2022
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial. JAMA network open, 2022, 11-01, Volume: 5, Issue:11 Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Rivaroxaban; Stroke	2022
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. Journal of vascular surgery, 2023, Volume: 77, Issue:4 Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Treatment Outcome	2023
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban. Thrombosis research, 2023, Volume: 222 Topics: Acenocoumarol; Anticoagulants; Aspirin; Hemorrhage; Humans; Ischemic Stroke; Pilot Projects; Pulmonary Embolism; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis	2023
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial. American heart journal, 2023, Volume: 258 Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2023
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. JAMA network open, 2023, 02-01, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban	2023
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra Trials, 2023, Mar-21, Volume: 24, Issue:1 Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome	2023
The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. Atherosclerosis, 2023, Volume: 372 Topics: Aspirin; Blood Pressure; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke	2023
Rivaroxaban in patients with abdominal aortic aneurysm and high-sensitivity C-reactive protein elevation (BANBOO): study protocol for a randomized, controlled trial. Trials, 2023, Jun-19, Volume: 24, Issue:1 Topics: Aortic Aneurysm, Abdominal; Aspirin; C-Reactive Protein; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Rivaroxaban; Thrombosis; Treatment Outcome	2023

Other Studies

184 other study(ies) available for aspirin and rivaroxaban

Article	Year
Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents. Journal of medicinal chemistry, 2011, Aug-11, Volume: 54, Issue:15 Topics: Adult; Animals; Anticoagulants; Factor Xa Inhibitors; Glucosides; Humans; Mice; Platelet Aggregation; Platelet Aggregation Inhibitors; Sulfuric Acid Esters; Thrombosis; Xanthones	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. European journal of medicinal chemistry, 2019, Feb-15, Volume: 164 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Multiple Myeloma; Platelet Aggregation Inhibitors; Protein Binding; Structure-Activity Relationship	2019
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Rivaroxaban (Xarelto) for acute coronary syndrome. The Medical letter on drugs and therapeutics, 2011, Dec-12, Volume: 53, Issue:1379-1380 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration	2011
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:12 Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; Rivaroxaban; Stents; Swine; Swine, Miniature; Thiophenes; Thrombosis; Ticlopidine	2012
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation". Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2013
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.". Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2013
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin	2014
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model. PloS one, 2014, Volume: 9, Issue:1 Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Blood Platelets; Dabigatran; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Fibrin; Humans; Lab-On-A-Chip Devices; Male; Microscopy, Confocal; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Thrombosis	2014
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA internal medicine, 2014, Volume: 174, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thromboembolism	2014
Triple antithrombotic therapy: risky but sometimes necessary. Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:3 Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K	2014
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. Journal of medical economics, 2014, Volume: 17, Issue:8 Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:10 Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin	2014
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China]. Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:5 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2014, Volume: 33, Issue:9 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Disease Progression; Health Resources; Humans; Markov Chains; Portugal; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Sensitivity and Specificity; Stroke; Time Factors; Warfarin	2014
Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury. The Kaohsiung journal of medical sciences, 2015, Volume: 31, Issue:3 Topics: Animals; Anticoagulants; Aryldialkylphosphatase; Aspirin; Cardiotonic Agents; Clopidogrel; Dipeptidases; Drug Evaluation, Preclinical; Enoxaparin; Femoral Artery; Heparin, Low-Molecular-Weight; Hindlimb; Kidney; Male; Malondialdehyde; Morpholines; Myocardium; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Reperfusion Injury; Rivaroxaban; Thiophenes; Ticlopidine	2015
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:6 Topics: Adenosine; Adult; Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Rivaroxaban; Thrombin; Ticagrelor; Ticlopidine	2015
Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment. JAMA internal medicine, 2015, Volume: 175, Issue:10 Topics: Acenocoumarol; Administration, Oral; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Monitoring; Drug Substitution; Epistaxis; Factor Xa Inhibitors; Female; Frail Elderly; Humans; Medication Therapy Management; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Renal Insufficiency; Rivaroxaban; Stroke	2015
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:7 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Dabigatran; Dipyridamole; Female; Guideline Adherence; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Ticlopidine; Warfarin	2015
Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clinical oral investigations, 2016, Volume: 20, Issue:6 Topics: Aged; Anticoagulants; Aspirin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Oral Hemorrhage; Oral Surgical Procedures; Postoperative Hemorrhage; Retrospective Studies; Risk Factors; Rivaroxaban	2016
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European journal of clinical pharmacology, 2016, Volume: 72, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Rivaroxaban; Warfarin	2016
[Case-control study on three antithrombotic agents for the prevention of venous thromboembolism after unilateral total knee arthroplasty]. Zhongguo gu shang = China journal of orthopaedics and traumatology, 2015, Volume: 28, Issue:10 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Case-Control Studies; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative Complications; Rivaroxaban; Venous Thromboembolism	2015
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation. Internal medicine journal, 2016, Volume: 46, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Australia; Dabigatran; Drug Prescriptions; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin	2016
Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. Journal of medical economics, 2016, Volume: 19, Issue:9 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Female; Humans; Japan; Male; Markov Chains; Middle Aged; Models, Econometric; Practice Guidelines as Topic; Rivaroxaban; Stroke; Warfarin	2016
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report. Minerva cardioangiologica, 2016, Volume: 64, Issue:4 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Rivaroxaban; Stroke; Tomography, X-Ray Computed; Treatment Failure	2016
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. The American journal of medicine, 2016, Volume: 129, Issue:11 Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Venous Thromboembolism	2016
Locked Away: Percutaneous Closure of a Malignant Left Atrial Appendage to Constrain an Unresolvable Thrombus. Circulation. Arrhythmia and electrophysiology, 2016, Volume: 9, Issue:8 Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Echocardiography, Transesophageal; Factor Xa Inhibitors; Humans; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Septal Occluder Device; Thrombosis; Ticlopidine; Vitamin K	2016
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Internal and emergency medicine, 2016, Volume: 11, Issue:7 Topics: Administration, Oral; Anticoagulants; Aspirin; Dabigatran; Humans; Italy; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Venous Thromboembolism; Vitamin K; Warfarin	2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. American heart journal, 2016, Volume: 179 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Therapy, Combination; Embolism; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Warfarin	2016
GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet (London, England), 2017, 05-06, Volume: 389, Issue:10081 Topics: Acute Coronary Syndrome; Aspirin; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2017
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. British journal of clinical pharmacology, 2017, Volume: 83, Issue:8 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Vitamin K	2017
Venous thromboembolism: Risk of recurrence lower with rivaroxaban than aspirin. Nature reviews. Cardiology, 2017, Volume: 14, Issue:5 Topics: Anticoagulants; Aspirin; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism	2017
Acute coronary syndromes: Similar bleeding risks with low-dose rivaroxaban versus aspirin. Nature reviews. Cardiology, 2017, 04-11, Volume: 14, Issue:5 Topics: Acute Coronary Syndrome; Aspirin; Double-Blind Method; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2017
Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial. The journal of trauma and acute care surgery, 2017, Volume: 82, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dabigatran; Female; Humans; Injury Severity Score; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Ticlopidine; Trauma Centers; Warfarin; Wounds and Injuries; Wounds, Nonpenetrating	2017
Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study. PloS one, 2017, Volume: 12, Issue:5 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Erythrocyte Transfusion; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Incidence; Male; Middle Aged; Polysaccharides; Postoperative Complications; Postoperative Hemorrhage; Republic of Korea; Risk Factors; Rivaroxaban; Venous Thromboembolism	2017
In VTE, extending anticoagulation with rivaroxaban vs aspirin reduced recurrence without increasing bleeding. Annals of internal medicine, 2017, 06-20, Volume: 166, Issue:12 Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism	2017
A comparison between vitamin K antagonists and new oral anticoagulants. British journal of clinical pharmacology, 2017, Volume: 83, Issue:11 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin	2017
[Continued anticoagulation for unprovoked venous thromboembolism: guidance through the maze of recent studies]. Nederlands tijdschrift voor geneeskunde, 2017, Volume: 161 Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism	2017
Antithrombotic therapy: COMPASS points to low-dose rivaroxaban and aspirin for secondary prevention. Nature reviews. Cardiology, 2017, Volume: 14, Issue:11 Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2017
Spontaneous Spinal Epidural Hematoma in a Patient on Rivaroxaban: Case Report and Literature Review. The Journal of emergency medicine, 2017, Volume: 53, Issue:4 Topics: Aged; Analgesia, Epidural; Aspirin; Back Pain; Emergency Service, Hospital; Factor Xa Inhibitors; Hematoma, Epidural, Spinal; Humans; Male; Pain Management; Platelet Aggregation Inhibitors; Rivaroxaban	2017
Review of article: Rivaroxaban with or without aspirin in stable cardiovascular disease. Eikelboom JW, Connolly SJ, Bosch J, et al. for the COMPASS investigators. Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing, 2017, Volume: 35, Issue:4 Topics: Aspirin; Cardiovascular Diseases; Factor Xa Inhibitors; Humans; Rivaroxaban	2017
In stable CVD, rivaroxaban plus aspirin reduced CV events and increased bleeding compared with aspirin alone. Annals of internal medicine, 2017, 11-21, Volume: 167, Issue:10 Topics: Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2017
Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. The American journal of medicine, 2018, Volume: 131, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Arteriovenous Malformations; Aspirin; Blood Transfusion; Case-Control Studies; Dabigatran; Diverticulum; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Hemorrhoids; Hospitalization; Humans; Male; Middle Aged; Peptic Ulcer; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin	2018
Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. Cardiovascular research, 2017, 12-01, Volume: 113, Issue:14 Topics: Aspirin; Atherosclerosis; Biomedical Research; Blood Platelets; Cardiology; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; History, 20th Century; History, 21st Century; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Treatment Outcome	2017
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European heart journal, 2018, 03-01, Volume: 39, Issue:9 Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Patient Selection; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Thrombosis	2018
Prevention: Rivaroxaban plus aspirin in CAD or PAD. Nature reviews. Cardiology, 2018, Volume: 15, Issue:1 Topics: Aspirin; Coronary Artery Disease; Double-Blind Method; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2018
Rivaroxaban with or without aspirin for prevention of cardiovascular disease. Coronary artery disease, 2018, Volume: 29, Issue:5 Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Clinical Decision-Making; Evidence-Based Medicine; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Thrombosis; Treatment Outcome	2018
Ranibizumab and digital ischemia. Journal de medecine vasculaire, 2018, Volume: 43, Issue:1 Topics: Aged, 80 and over; Angiogenesis Inhibitors; Angioplasty; Aspirin; Combined Modality Therapy; Female; Fingers; Heparin, Low-Molecular-Weight; Humans; Iloprost; Intravitreal Injections; Ischemia; Macular Degeneration; Radial Artery; Ranibizumab; Rivaroxaban; Thrombectomy; Thrombosis; Ulnar Artery; Vascular Endothelial Growth Factor A	2018
Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease. Annals of vascular surgery, 2018, Volume: 49 Topics: Aspirin; Behcet Syndrome; Endovascular Procedures; Factor Xa Inhibitors; Femoral Vein; Humans; Iliac Vein; Immunosuppressive Agents; Male; May-Thurner Syndrome; Mechanical Thrombolysis; Phlebography; Platelet Aggregation Inhibitors; Recurrence; Rivaroxaban; Stents; Thrombectomy; Treatment Outcome; Ultrasonography, Interventional; Venous Thrombosis; Young Adult	2018
Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Blood Loss, Surgical; Enoxaparin; Female; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Thrombosis	2018
Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective. Internal and emergency medicine, 2018, Volume: 13, Issue:7 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Drug Monitoring; Female; Hemorrhage; Humans; Rivaroxaban	2018
Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation. Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:3(Special) Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Rivaroxaban; Venous Thrombosis	2018
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? European heart journal, 2019, 05-07, Volume: 40, Issue:18 Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Stroke; Thrombosis; Vascular Diseases	2019
What now for embolic stroke of undetermined source? Nature reviews. Neurology, 2018, Volume: 14, Issue:9 Topics: Anticoagulants; Aspirin; Brain Ischemia; Clinical Trials as Topic; Humans; Intracranial Embolism; Rivaroxaban; Secondary Prevention; Stroke	2018
Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital. Journal of pharmacy practice, 2020, Volume: 33, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dabigatran; Drug Combinations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Hospitals, Urban; Humans; Male; Middle Aged; Pyridones; Retrospective Studies; Rivaroxaban	2020
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. The Journal of arthroplasty, 2018, Volume: 33, Issue:11 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin	2018
Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction. BMC family practice, 2018, 07-18, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Germany; Humans; Male; Middle Aged; Phenprocoumon; Platelet Aggregation Inhibitors; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult	2018
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. Blood advances, 2018, 07-24, Volume: 2, Issue:14 Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Receptors, Purinergic P2Y12; Rivaroxaban; Thrombosis	2018
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis research, 2018, Volume: 168 Topics: Aspirin; Factor Xa Inhibitors; Female; Humans; Male; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Venous Thromboembolism	2018
Critical appraisal of the COMPASS trial. European heart journal. Cardiovascular pharmacotherapy, 2018, 10-01, Volume: 4, Issue:4 Topics: Aspirin; Cardiovascular Diseases; Humans; Orientation; Rivaroxaban	2018
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty. The Journal of the American Academy of Orthopaedic Surgeons, 2018, Oct-01, Volume: 26, Issue:19 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clinical Decision-Making; Dabigatran; Databases, Factual; Enoxaparin; Female; Fondaparinux; Humans; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Rivaroxaban; Venous Thrombosis; Warfarin	2018
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. Chest, 2018, Volume: 154, Issue:6 Topics: Anticoagulants; Aspirin; Cost Savings; Dose-Response Relationship, Drug; Drug Monitoring; Female; Health Care Costs; Hemorrhage; Humans; Male; Middle Aged; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Venous Thromboembolism	2018
Patients with Peripheral Artery Disease in the COMPASS Trial. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018, Volume: 56, Issue:6 Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Adjustment; Rivaroxaban; Secondary Prevention	2018
24-year-old with history of smoking tobacco and cannabis · dyspnea · chest tightness. The Journal of family practice, 2018, Volume: 67, Issue:9 Topics: Adult; Antihypertensive Agents; Aspirin; Chest Pain; Coronary Vasospasm; Dyspnea; Humans; Lisinopril; Male; Marijuana Smoking; Metoprolol; Muscle Tonus; Rivaroxaban; Tobacco Smoking; Treatment Outcome; Young Adult	2018
In embolic stroke of undetermined source, rivaroxaban vs aspirin did not reduce recurrence and increased bleeding. Annals of internal medicine, 2018, 09-18, Volume: 169, Issue:6 Topics: Aspirin; Hemorrhage; Humans; Rivaroxaban; Stroke	2018
Impact of oral anticoagulants on 30-day readmission: a study from a single academic centre. BMJ evidence-based medicine, 2019, Volume: 24, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Comorbidity; Confounding Factors, Epidemiologic; Emergency Service, Hospital; Facilities and Services Utilization; Female; Hemorrhage; Humans; Illinois; Length of Stay; Male; Middle Aged; Patient Readmission; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Rivaroxaban; Warfarin	2019
Optimal stroke prevention in patients with patent foramen ovale. The Lancet. Neurology, 2018, Volume: 17, Issue:12 Topics: Aspirin; Foramen Ovale, Patent; Humans; Rivaroxaban; Secondary Prevention; Stroke	2018
Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease? Circulation, 2018, 08-28, Volume: 138, Issue:9 Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Rivaroxaban; Thrombosis; Treatment Outcome	2018
Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future cardiology, 2018, Volume: 14, Issue:6 Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome	2018
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. European journal of preventive cardiology, 2019, Volume: 26, Issue:8 Topics: Aged; Aspirin; Australia; Carotid Artery Diseases; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Peripheral Arterial Disease; Quality of Life; Quality-Adjusted Life Years; Recurrence; Rivaroxaban; Time Factors; Treatment Outcome	2019
Advances in Antithrombotic Therapy. Arteriosclerosis, thrombosis, and vascular biology, 2019, Volume: 39, Issue:1 Topics: Aspirin; Clinical Trials as Topic; Factor XI; Factor XII; Fibrinolytic Agents; Humans; Rivaroxaban; Thrombosis	2019
Aspirin versus rivaroxaban in postoperative bleeding after total knee arthroplasty: a retrospective case-matched study. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2019, Volume: 29, Issue:4 Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion; Chemoprevention; Drainage; Factor Xa Inhibitors; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Rivaroxaban; Venous Thromboembolism	2019
Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events. The Medical letter on drugs and therapeutics, 2018, Dec-03, Volume: 60, Issue:1561 Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrence; Rivaroxaban; Secondary Prevention; Treatment Outcome	2018
Antithrombotic Therapy Following CABG: For the Patient, Not the Bypass Graft. Journal of the American College of Cardiology, 2019, 01-22, Volume: 73, Issue:2 Topics: Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Rivaroxaban	2019
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. The Journal of arthroplasty, 2019, Volume: 34, Issue:4 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Databases, Factual; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Orthopedic Procedures; Orthopedics; Practice Patterns, Physicians'; Risk Factors; Rivaroxaban; United States; Venous Thromboembolism; Venous Thrombosis; Warfarin	2019
Adding rivaroxaban to aspirin after CABG surgery. Nature reviews. Cardiology, 2019, Volume: 16, Issue:3 Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Thrombosis; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Treatment Outcome	2019
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. Circulation research, 2019, Volume: 124, Issue:3 Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Plaque, Atherosclerotic; Rivaroxaban; Thrombosis	2019
Stroke prevention in atrial fibrillation: Closing the gap. American heart journal, 2019, Volume: 210 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin	2019
Optimal stroke prevention in patients with PFO. The Lancet. Neurology, 2019, Volume: 18, Issue:3 Topics: Aspirin; Foramen Ovale, Patent; Humans; Recurrence; Rivaroxaban; Stroke	2019
Zeitschrift fur Orthopadie und Unfallchirurgie, 2019, Volume: 157, Issue:1 Topics: Arthroplasty, Replacement, Knee; Aspirin; Humans; Postoperative Complications; Rivaroxaban; Thromboembolism	2019
Stroke in a young man: a late complication of radiation therapy. BMJ case reports, 2019, Feb-22, Volume: 12, Issue:2 Topics: Adult; Anticholesteremic Agents; Aortic Valve; Aspirin; Echocardiography, Transesophageal; Factor Xa Inhibitors; Heart Valve Diseases; Humans; Male; Paresis; Rivaroxaban; Rosuvastatin Calcium; Stroke; Treatment Outcome	2019
Non-vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis. Kardiologia polska, 2019, Feb-18, Volume: 77, Issue:4 Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiology; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Poland; Rivaroxaban; Societies, Medical; Thromboembolism	2019
Clinical outcomes and risk factors of thromboprophylaxis with rivaroxaban versus aspirin in patients undergoing hip arthroplasty in low-incidence population: A nationwide study in Korea. Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Female; Follow-Up Studies; Humans; Incidence; Male; Medical History Taking; Middle Aged; Postoperative Hemorrhage; Republic of Korea; Risk Factors; Rivaroxaban; Sex Factors; Treatment Outcome; Venous Thromboembolism	2019
External applicability of the COMPASS trial: the Western Denmark Heart Registry. European heart journal. Cardiovascular pharmacotherapy, 2019, 10-01, Volume: 5, Issue:4 Topics: Aged; Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Coronary Angiography; Coronary Artery Disease; Denmark; Drug Therapy, Combination; Eligibility Determination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Patient Selection; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Registries; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome	2019
Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist: Aspirin or Rivaroxaban for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty. American journal of physical medicine & rehabilitation, 2019, Volume: 98, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Peer Review; Physiatrists; Rivaroxaban; Venous Thromboembolism	2019
Renal Dysfunction: The Wake-Up Alarm for Chronic Vascular Disease. Journal of the American College of Cardiology, 2019, 05-14, Volume: 73, Issue:18 Topics: Aspirin; Factor Xa Inhibitors; Humans; Kidney Diseases; Rivaroxaban; Vascular Diseases	2019
Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed. Journal of the American College of Cardiology, 2019, 05-14, Volume: 73, Issue:18 Topics: Aspirin; Coronary Artery Bypass; Factor Xa Inhibitors; Platelet Aggregation Inhibitors; Rivaroxaban	2019
Reply: Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed. Journal of the American College of Cardiology, 2019, 05-14, Volume: 73, Issue:18 Topics: Aspirin; Coronary Artery Bypass; Factor Xa Inhibitors; Platelet Aggregation Inhibitors; Rivaroxaban	2019
Thromboprophylaxis by rivaroxaban, aspirin, both, or placebo after hospitalization for medical illness. Thrombosis research, 2019, Volume: 180 Topics: Aspirin; Factor Xa Inhibitors; Hospitalization; Humans; Placebo Effect; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombosis; Venous Thromboembolism	2019
Does rivaroxaban have a role in treating patients with PAD? JAAPA : official journal of the American Academy of Physician Assistants, 2019, Volume: 32, Issue:7 Topics: Aspirin; Humans; Peripheral Arterial Disease; Rivaroxaban	2019
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. Journal of the American College of Cardiology, 2019, 07-02, Volume: 73, Issue:25 Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male; Myocardial Ischemia; Prospective Studies; Registries; Risk Assessment; Rivaroxaban	2019
Heterogeneity of Risk and Benefit in Subgroups of COMPASS: Relatively Similar But Absolutely Different. Journal of the American College of Cardiology, 2019, 07-02, Volume: 73, Issue:25 Topics: Aspirin; Factor Xa Inhibitors; Platelet Aggregation Inhibitors; Rivaroxaban	2019
Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth. Gastroenterology, 2019, Volume: 157, Issue:3 Topics: Aspirin; Humans; Proton Pump Inhibitors; Proton Pumps; Rivaroxaban	2019
Is Embolic Stroke of Undetermined Source Shrinking? Stroke, 2019, Volume: 50, Issue:9 Topics: Aspirin; Carotid Artery Diseases; Embolism; Humans; Rivaroxaban; Stroke	2019
Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure. Circulation, 2019, 08-13, Volume: 140, Issue:7 Topics: Aspirin; Coronary Artery Disease; Heart Failure; Humans; Peripheral Arterial Disease; Rivaroxaban	2019
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists. European journal of clinical investigation, 2019, Volume: 49, Issue:10 Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles	2019
Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS? European heart journal, 2019, 12-07, Volume: 40, Issue:46 Topics: Aspirin; Cardiovascular Diseases; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2019
Anticoagulation in Revision Total Joint Arthroplasty: A Retrospective Review of 1917 Cases. Orthopedics, 2019, Nov-01, Volume: 42, Issue:6 Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Male; Middle Aged; Postoperative Complications; Postoperative Period; Reoperation; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin	2019
Is Bleeding Always Bad?: Bad Boy Bleeding. Journal of the American College of Cardiology, 2019, 09-24, Volume: 74, Issue:12 Topics: Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Peripheral Arterial Disease; Rivaroxaban	2019
[Treatment of Patients with Stable Manifestations of Atherosclerotic Vascular Disease: New Possibilities (Conclusion of the Council of Experts from November 16, 2018, Rostov-on-Don)]. Kardiologiia, 2019, Sep-17, Volume: 59, Issue:9 Topics: Aspirin; Atherosclerosis; Blood Coagulation; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2019
[Dual Pathway Inhibition in Atherosclerosis - Which Patients Benefit?] Deutsche medizinische Wochenschrift (1946), 2019, Volume: 144, Issue:20 Topics: Aspirin; Atherosclerosis; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2019
Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease. Annals of internal medicine, 2019, 10-15, Volume: 171, Issue:8 Topics: Aspirin; Double-Blind Method; Humans; Pantoprazole; Proton Pump Inhibitors; Rivaroxaban	2019
Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. Orthopaedic surgery, 2019, Volume: 11, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Hip Fractures; Humans; Male; Middle Aged; Postoperative Complications; Postoperative Period; Retrospective Studies; Rivaroxaban; Venous Thromboembolism	2019
Reply. Gastroenterology, 2020, Volume: 158, Issue:1 Topics: Aspirin; Double-Blind Method; Humans; Pantoprazole; Rivaroxaban	2020
Pantoprazole in Prevention of Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin-A Short Word of Caution. Gastroenterology, 2020, Volume: 158, Issue:1 Topics: Aspirin; Double-Blind Method; Factor Xa Inhibitors; Humans; Pantoprazole; Platelet Aggregation Inhibitors; Rivaroxaban	2020
Pantoprazole in COMPASS- No Prevention of Gastroduodenal Events or Other Useful Net Results. Gastroenterology, 2020, Volume: 158, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Humans; Pantoprazole; Rivaroxaban	2020
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment. JAMA neurology, 2020, 01-01, Volume: 77, Issue:1 Topics: Aspirin; Atrial Fibrillation; Computed Tomography Angiography; Humans; Rivaroxaban; Stroke	2020
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment-Reply. JAMA neurology, 2020, 01-01, Volume: 77, Issue:1 Topics: Aspirin; Atrial Fibrillation; Computed Tomography Angiography; Humans; Rivaroxaban; Stroke	2020
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovascular research, 2020, 09-01, Volume: 116, Issue:11 Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Markov Chains; Models, Economic; Peripheral Arterial Disease; Progression-Free Survival; Quality of Life; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Time Factors; United Kingdom	2020
[PEGASUS or COMPASS? A guide for a wise clinical choice.] Recenti progressi in medicina, 2019, Volume: 110, Issue:11 Topics: Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Registries; Risk; Rivaroxaban; Ticagrelor	2019
Long-term Renal Effects of Proton Pump Inhibitor Use. Gastroenterology, 2020, Volume: 158, Issue:4 Topics: Aspirin; Humans; Proton Pump Inhibitors; Rivaroxaban	2020
Safety of Proton Pump Inhibitors Questioned Based on a Large Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 2020, Volume: 158, Issue:4 Topics: Aspirin; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rivaroxaban	2020
What Is the Optimal Follow-up Time to Ascertain the Safety of Proton Pump Inhibitors? Gastroenterology, 2020, Volume: 158, Issue:4 Topics: Aspirin; Follow-Up Studies; Humans; Lansoprazole; Proton Pump Inhibitors; Rivaroxaban	2020
Reply. Gastroenterology, 2020, Volume: 158, Issue:4 Topics: Aspirin; Humans; Proton Pump Inhibitors; Rivaroxaban	2020
Proton Pump Inhibitor Therapy and Fracture Risk: Discrepancy of Results Between Observational and Interventional Studies. Gastroenterology, 2020, Volume: 158, Issue:4 Topics: Aspirin; Hip Fractures; Humans; Proton Pump Inhibitors; Research; Rivaroxaban	2020
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. European journal of preventive cardiology, 2020, Volume: 27, Issue:13 Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Models, Economic; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Rivaroxaban	2020
Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement. International journal of clinical pharmacy, 2020, Volume: 42, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Delayed-Action Preparations; Elective Surgical Procedures; Enoxaparin; Female; Humans; Ireland; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Risk Factors; Rivaroxaban; Socioeconomic Factors; Venous Thromboembolism; Young Adult	2020
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?] Kardiologiia, 2020, Mar-05, Volume: 60, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Rivaroxaban	2020
Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers. Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:6 Topics: Age Factors; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Early Termination of Clinical Trials; Eicosapentaenoic Acid; Hemorrhage; Humans; Medicare; Models, Economic; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; United States	2020
[Mortality benefit with different antithrombotic therapies in patients with stable vascular disease: from pathophysiology to the clinical impact in the real world. The COMPASS study]. Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:7 Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban; Vascular Diseases	2020
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry. European heart journal. Quality of care & clinical outcomes, 2021, 09-16, Volume: 7, Issue:5 Topics: Aspirin; Coronary Artery Disease; Humans; Myocardial Infarction; Registries; Rivaroxaban	2021
Multimodal prophylaxis in patients with a history of venous thromboembolism undergoing primary elective hip arthroplasty. The bone & joint journal, 2020, Volume: 102-B, Issue:7_Supple_B Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Early Ambulation; Elective Surgical Procedures; Female; Follow-Up Studies; Heparin; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Risk Factors; Rivaroxaban; Venous Thromboembolism; Warfarin	2020
The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2021, 05-01, Volume: 97, Issue:6 Topics: Aspirin; Atherosclerosis; Coronary Artery Disease; Factor Xa Inhibitors; Humans; Rivaroxaban; Treatment Outcome	2021
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation]. Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:14 Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K	2020
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. Annales de cardiologie et d'angeiologie, 2020, Volume: 69, Issue:4 Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Administration Schedule; Female; Follow-Up Studies; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Patient Selection; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Rivaroxaban; Stroke; Thrombosis; Time Factors; Treatment Outcome	2020
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi La Revue de medecine interne, 2020, Volume: 41, Issue:8 Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke; Magnetic Resonance Imaging; Myocardial Infarction; Peripheral Arterial Disease; Rivaroxaban; Stroke	2020
Proton pump inhibitors and chronic kidney disease: Reevaluating the evidence from a randomized controlled trial. Pharmacoepidemiology and drug safety, 2021, Volume: 30, Issue:1 Topics: Aspirin; Humans; Proton Pump Inhibitors; Renal Insufficiency, Chronic; Rivaroxaban	2021
Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3 Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Health Expenditures; Humans; Markov Chains; Peripheral Arterial Disease; Quality-Adjusted Life Years; Rivaroxaban; Secondary Prevention; Taiwan	2021
Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study. Pharmacoepidemiology and drug safety, 2020, Volume: 29, Issue:12 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke	2020
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. Stroke, 2020, Volume: 51, Issue:10 Topics: Aged; Aspirin; Brain; Brain Infarction; Cognitive Dysfunction; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke; Treatment Outcome	2020
Rivaroxaban in COMPASS trial. Vnitrni lekarstvi, 2020,Spring, Volume: 66, Issue:3 Topics: Aspirin; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Humans; Rivaroxaban; Secondary Prevention	2020
Desmopressin with four-factor prothrombin complex concentrate for life-threatening bleeding: A case series. The American journal of emergency medicine, 2020, Volume: 38, Issue:12 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation Factors; Cerebral Hemorrhage, Traumatic; Cerebral Intraventricular Hemorrhage; Clopidogrel; Deamino Arginine Vasopressin; Female; Fractures, Bone; Hematoma; Hematoma, Subdural, Intracranial; Hemostatics; Humans; International Normalized Ratio; Intracranial Hemorrhage, Traumatic; Male; Middle Aged; Pelvic Bones; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Subarachnoid Hemorrhage, Traumatic; Thrombosis; Warfarin	2020
Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery. Scientific reports, 2020, 11-09, Volume: 10, Issue:1 Topics: Animals; Arteries; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Factor Xa Inhibitors; Leukocytes; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombosis	2020
Rivaroxaban in Peripheral Artery Disease after Revascularization. The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21 Topics: Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban	2020
Rivaroxaban in Peripheral Artery Disease after Revascularization. The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21 Topics: Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban	2020
Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply. The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21 Topics: Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban	2020
Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model. Journal of atherosclerosis and thrombosis, 2022, Jan-01, Volume: 29, Issue:1 Topics: Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Factor Xa Inhibitors; Graft Occlusion, Vascular; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Swine; Tomography, Optical Coherence	2022
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State. Annals of neurology, 2021, Volume: 89, Issue:3 Topics: Aged; Aged, 80 and over; Animals; Antithrombins; Arachidonic Acid; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Chlorides; Computed Tomography Angiography; Dabigatran; Deprescriptions; Factor Xa Inhibitors; Female; Ferric Compounds; Humans; Ischemic Stroke; Magnetic Resonance Angiography; Male; Mean Platelet Volume; Mice; Noxae; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Substance Withdrawal Syndrome; Thrombin; Thrombophilia; X-Ray Microtomography	2021
VOYAGER PAD contributes to medical therapy for peripheral artery disease. Journal of vascular surgery, 2020, Volume: 72, Issue:6 Topics: Aspirin; Drug Therapy, Combination; Endovascular Procedures; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome; Vascular Surgical Procedures	2020
Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Rivaroxaban	2020
Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. Medicine, 2020, Dec-04, Volume: 99, Issue:49 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion; Hemorrhage; Humans; Meta-Analysis as Topic; Pulmonary Embolism; Research Design; Rivaroxaban; Surgical Wound Infection; Systematic Review as Topic; Venous Thromboembolism; Venous Thrombosis	2020
Letter by McCaw et al Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". Circulation, 2021, 01-05, Volume: 143, Issue:1 Topics: Aspirin; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Vascular Diseases	2021
Response by Fox to Letter Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". Circulation, 2021, 01-05, Volume: 143, Issue:1 Topics: Aspirin; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Vascular Diseases	2021
[Antithrombotic therapy after peripheral revascularization]. Deutsche medizinische Wochenschrift (1946), 2021, Volume: 146, Issue:3 Topics: Aspirin; Endovascular Procedures; Fibrinolytic Agents; Humans; Lower Extremity; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Rivaroxaban	2021
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. Clinical drug investigation, 2021, Volume: 41, Issue:5 Topics: Aged; Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Italy; Male; Middle Aged; Peripheral Arterial Disease; Quality-Adjusted Life Years; Rivaroxaban; Treatment Outcome	2021
Rivaroxaban reduces thromboxane induced platelet aggregation - the forgotten compass arm? Platelets, 2021, 11-17, Volume: 32, Issue:8 Topics: Aspirin; Chronic Disease; Drug Therapy, Combination; Heart Diseases; Humans; Platelet Aggregation; Platelet Function Tests; Rivaroxaban; Thromboxanes	2021
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. BMC cardiovascular disorders, 2021, 03-31, Volume: 21, Issue:1 Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolic Stroke; Hemorrhage; Humans; Ischemic Stroke; Models, Economic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Time Factors; Treatment Outcome	2021
Features of Antithrombotic Therapy in Patients with Multifocal Arterial Disease. Kardiologiia, 2021, Mar-30, Volume: 61, Issue:3 Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2021
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. JAMA internal medicine, 2021, 06-01, Volume: 181, Issue:6 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism	2021
Early stopping of a randomised trial for efficacy: a medical, ethical and regulatory challenge. Heart (British Cardiac Society), 2021, Volume: 107, Issue:14 Topics: Aspirin; Continuity of Patient Care; Coronary Disease; Early Termination of Clinical Trials; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome	2021
A retrospective analysis of bleeding risk with rivaroxaban, enoxaparin, and aspirin following total joint arthroplasty or revision. Pharmacotherapy, 2021, Volume: 41, Issue:7 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Postoperative Hemorrhage; Reoperation; Retrospective Studies; Risk Assessment; Rivaroxaban; Venous Thromboembolism	2021
Antithrombotic Therapy to Reduce Mortality in Patients With Atherosclerosis: 2 Pathways to a Single Goal. Journal of the American College of Cardiology, 2021, 07-06, Volume: 78, Issue:1 Topics: Aspirin; Atherosclerosis; Fibrinolytic Agents; Goals; Humans; Rivaroxaban	2021
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2021, Volume: 62, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Female; France; Hospitalization; Humans; Incidence; Ischemia; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Registries; Retrospective Studies; Rivaroxaban; Treatment Outcome; Young Adult	2021
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European journal of preventive cardiology, 2022, 05-05, Volume: 29, Issue:5 Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke	2022
Low-dose rivaroxaban plus aspirin for elderly patients with symptomatic peripheral artery disease: is it worth the bleeding risk? European heart journal, 2021, 10-14, Volume: 42, Issue:39 Topics: Aged; Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban	2021
[Current opportunities for secondary prevention of atherothrombotic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2021, Volume: 121, Issue:8 Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Stroke	2021
Lesson learned from the COMPASS and VOYAGER PAD trials: dual pathway inhibition as a new antithrombotic paradigm? European journal of preventive cardiology, 2022, 05-05, Volume: 29, Issue:5 Topics: Aspirin; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2022
Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularization. International angiology : a journal of the International Union of Angiology, 2022, Volume: 41, Issue:1 Topics: Aspirin; Female; Humans; Lower Extremity; Male; Peripheral Arterial Disease; Prevalence; Risk Factors; Rivaroxaban; Treatment Outcome	2022
Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2022, Volume: 63, Issue:2 Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Denmark; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome; Vascular Surgical Procedures	2022
Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants. Journal of pharmacy practice, 2023, Volume: 36, Issue:3 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Interactions; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban	2023
Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis. Medicine, 2022, Feb-11, Volume: 101, Issue:6 Topics: Aspirin; Coronary Artery Disease; Humans; Meta-Analysis as Topic; Myocardial Ischemia; Research Design; Rivaroxaban; Systematic Reviews as Topic; Treatment Outcome	2022
Effect of combining aspirin and rivaroxaban on atherosclerosis in mice. Atherosclerosis, 2022, Volume: 345 Topics: Animals; Aorta; Apolipoproteins E; Aspirin; Atherosclerosis; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, LDL; Rivaroxaban	2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-29, Volume: 8, Issue:7 Topics: Aspirin; Clopidogrel; Cyclooxygenase 1; Fibrinolytic Agents; Humans; Peptides; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Thrombin; Rivaroxaban; Thrombin; Thromboplastin; Ticagrelor	2022
[COMPASS study results as a foundation for new treatment approach for neurological patients. Opinion of the expert council of december 18, 2021]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:4 Topics: Aspirin; Drug Therapy, Combination; Humans; Rivaroxaban; Stroke	2022
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 06-21, Volume: 145, Issue:25 Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Venous Thromboembolism	2022
[Recent developments in secondary cardiovascular prevention: the pros and cons of dual pathway inhibition]. Nederlands tijdschrift voor geneeskunde, 2022, 06-22, Volume: 166 Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2022
Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. European journal of clinical pharmacology, 2022, Volume: 78, Issue:9 Topics: Aspirin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemia; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Rivaroxaban	2022
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:6 Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Secondary Prevention; Ticagrelor; Treatment Outcome	2022
Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty. Foot & ankle international, 2022, Volume: 43, Issue:10 Topics: Ankle; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; Cost-Benefit Analysis; Enoxaparin; Humans; Postoperative Complications; Rivaroxaban; Venous Thromboembolism; Warfarin	2022
Potent antithrombotic treatments in Asian vs. non-Asian patients. European heart journal, 2022, 10-07, Volume: 43, Issue:37 Topics: Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Rivaroxaban	2022
Best Medical Treatment: What About the COMPASS Trial Strategy? Acta medica portuguesa, 2022, 10-03, Volume: 35, Issue:10 Topics: Aspirin; Cohort Studies; Humans; Risk Factors; Rivaroxaban; Vascular Surgical Procedures	2022
Rivaroxaban, a New Molecule with Potential to Balance Bleeding Risk and Ischemic Events in Patients with Chronic Coronary Syndrome. The Journal of the Association of Physicians of India, 2022, Volume: 70, Issue:8 Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2022
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. The Canadian journal of cardiology, 2023, Volume: 39, Issue:2 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Stroke; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke	2023
Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. International journal of cardiology, 2023, Jan-15, Volume: 371 Topics: Aged; Aspirin; China; Coronary Artery Disease; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Humans; Markov Chains; Peripheral Arterial Disease; Quality-Adjusted Life Years; Rivaroxaban	2023
The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:2 Topics: Animals; Aspirin; Biomarkers; Factor Xa Inhibitors; Heart Injuries; Inflammation; Isoproterenol; Male; Oxidative Stress; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Rivaroxaban	2023
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease]. Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:12 Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Rivaroxaban	2022
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. Journal of the American Heart Association, 2022, 12-20, Volume: 11, Issue:24 Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention	2022
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances. Kardiologia polska, 2022, Volume: 80, Issue:12 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Heart Failure; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Rivaroxaban; Thrombosis	2022
Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. Journal of cardiovascular pharmacology, 2023, 02-01, Volume: 81, Issue:2 Topics: Aged; Aspirin; Atherosclerosis; Biomarkers; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Growth Differentiation Factor 15; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban	2023
A hybrid automated event adjudication system for clinical trials. Clinical trials (London, England), 2023, Volume: 20, Issue:2 Topics: Aspirin; Double-Blind Method; Embolic Stroke; Embolism; Factor Xa; Factor Xa Inhibitors; Humans; Myocardial Infarction; Rivaroxaban; Stroke	2023
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. The Journal of arthroplasty, 2023, Volume: 38, Issue:8 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism	2023
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou European heart journal. Cardiovascular pharmacotherapy, 2023, 04-10, Volume: 9, Issue:3 Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Stroke; Ticagrelor	2023
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2023, Volume: 26 Topics: Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Eye; Hemorrhage; Humans; Japan; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Warfarin	2023